Medicines
(Prescription Only) (Jersey) Order 1997[1]
THE HEALTH AND SOCIAL SERVICES COMMITTEE in pursuance of Articles 57 and 110 of the Medicines
(Jersey) Law 1995, after consultation with the Medicines
Advisory Council and having otherwise complied with Article 110 of the Law,
orders as follows –
Commencement [see endnotes]
1 Interpretation
(1) In
this Order, unless the context otherwise requires –
“aerosol”
means a product that is dispersed from its container by a propellent gas or
liquid;
“controlled drug”
has the same meaning as it has in Article 3 of the Misuse of Drugs
(Jersey) Law 1978;
“cyanogenetic
substances” means preparations –
(a) that are presented for sale or supply under
the name of, or as containing, amygdalin, laetrile or vitamin B17; or
(b) that contain more than 0.1% by weight of any
substance having the formula α-cyanobenzyl-6-O-ß-d-glucopyranosyl-ß-d-glucopyranoside or α-cyanobenzyl-ß-d-glucopyranosiduronic acid;
“dosage unit”
means –
(a) where a medicinal product is in the form of
a tablet or capsule or is an article in some other similar pharmaceutical form,
that tablet, capsule or other article; and
(b) where a medicinal product is not in any such
form, the quantity of the product that is used as the unit by reference to
which the dose is measured;
“external use”
means application to the skin, hair, teeth, mucosa of the mouth, throat, nose,
ear, eye, vagina or anal canal, when a local action only is intended and
extensive systemic absorption is unlikely to occur; but does not mean
application by means of a throat spray, throat pastille, throat lozenge, throat
tablet, nasal drop, nasal spray, nasal inhalation or teething preparation;
“health prescription”
means a prescription described in Article 15(2) of the Health Insurance
(Jersey) Law 1967;
“health
record” has the same meaning as in the Data Protection
(Jersey) Law 2018;
“inhaler” does
not include an aerosol;
“Law” means
the Medicines
(Jersey) Law 1995;
“master” has
the same meaning as it has in the Merchant Shipping Act 1894 of the United
Kingdom;
“maximum daily dose”
or “MDD” means, in relation to a substance contained in the amount
of a medicinal product for internal use, the recommended maximum quantity to be
taken or administered in a period of 24 hours;
“maximum dose”
or “MD” means, in relation to a substance contained in the amount
of a medicinal product for internal use, the recommended maximum quantity to be
taken or administered at any one time;
“maximum strength”
means such of the following as may be specified –
(a) the maximum quantity of a substance by
weight or volume contained in a dosage unit of a medicinal product;
(b) the maximum number of units of activity
contained in a dosage unit or a weight of a medicinal product; and
(c) the maximum percentage of a substance
contained in a medicinal product calculated in terms of weight in weight,
weight in volume, volume in weight or volume in volume, as appropriate;
“medicinal product”
does not include a veterinary drug;
“occupational health
scheme” means a scheme in which a person in the course of a business
carried on by him or her provides facilities for his or her employees, for the
treatment or prevention of disease;
“operator”, in
relation to an aircraft, means the person for the time being having the
management of the aircraft;
“parenteral
administration” means administration by breach of the skin or mucous
membrane;
“prescription only
medicine” means a medicinal product that is specified by this Order as a
prescription only medicine;
“registered
optometrist” has the same meaning as it has in Article 1(1) of the Opticians
(Registration) (Jersey) Law 1962;
“repeatable
prescription” means a prescription containing a direction that it shall
or may be dispensed more than once;
“soaps” means
any compounds of a fatty acid with an alkali or amine;
“state registered
paramedic” means a person who is registered in the register established
and maintained under section 60 and paragraph 1(a) of Schedule 3 to the Health
Act 1999 of the United Kingdom;
“supplementary
prescriber” means any of the following –
(a) a midwife or nurse, whose entry on the
register established and maintained under article 5 of the Nursing and
Midwifery Order 2001 of the United Kingdom indicates that he or she is, or may
act as, only a supplementary prescriber;
(b) an optometrist, whose entry on the register
established and maintained under section 7(a) of the Opticians Act 1989 of
the United Kingdom indicates that he or she is, or may act as, only a
supplementary prescriber;
(c) a pharmacist, whose entry on the register
established and maintained under article 19 of the Pharmacy Order 2010 of
the United Kingdom indicates that he or she is, or may act as, only a supplementary
prescriber;
(d) a physiotherapist, podiatrist or
radiographer, whose entry on the register established and maintained under
article 5 of the Health and Social Work Professions Order 2001 of the
United Kingdom indicates that he or she is, or may act as, only a supplementary
prescriber.
“unit preparation” means a
preparation (including a mother tincture) that is prepared by a process of
solution, extraction or trituration, with a view to being diluted tenfold or
one hundredfold (either once or repeatedly) in an inert diluent and then used
either in that diluted form or (where applicable) by impregnating tablets,
granules, powders or other inert substances.[2]
(2) In
this Order –
(a) in Schedules 1 and 2, the following
abbreviations are used –
“g” for gram;
“iu” for international
unit of activity;
“mcg” for microgram;
“mg” for milligram; and
“ml” for millilitre; and
(b) in Schedule 1 –
(i) entries in any of
columns 2, 3 and 4 of Parts 1 and 2 relate only to the substances
specified in column 1 against which they appear,
(ii) where,
in relation to a particular substance specified in column 1, an entry in any of
columns 2, 3 and 4 bears a number or letter, that entry relates only to entries
in the other of columns 2, 3 and 4 that bear the same number or letter, and
(iii) the
entries in column 4 of Part 1 shall be read subject to the note at the end
of that Part.
(3) Without
prejudice to Article 10 of the Interpretation
(Jersey) Law 1954, every provision in the Medicines
(Jersey) Law 1995 that relates in any other way to its
interpretation shall also apply in the same way to this Order, unless the
context otherwise requires.
2 Prescription
only medicines
The following
descriptions and classes of medicinal products are specified for the purposes
of Article 57(1)(a) of the Law, and are accordingly prescription only
medicines, namely –
(a) medicinal
products that consist of or contain a substance specified in column 1 of Part 1
of Schedule 1 to this Order;
(b) medicinal
products that are controlled drugs;
(c) medicinal
products that are for parenteral administration, whether or not they fall
within sub-paragraph (a) or (b) of this paragraph;
(d) medicinal
products that –
(i) are not of a description and do not
fall within a class specified in any of sub-paragraphs (a), (b) and (c) of
this paragraph,
(ii) are of a description in respect of
which the conditions in Article 58(1) of the Law are fulfilled, and
(iii) are products in respect of which a product
licence is granted, after the commencement of this Order, containing a
provision to the effect that the method of sale or supply of the medicinal
product is to be only in accordance with a prescription given by a person who
is an appropriate practitioner; and
(e) cyanogenetic
substances, other than preparations for external use.[3]
3 Medicinal
products that are not prescription only medicines
(1) Notwithstanding
Article 2, a medicinal product shall not be a prescription only medicine
by reason that it consists of or contains a substance specified in column 1 of Part 1
of Schedule 1, where –
(a) in relation to that substance there is an
entry in any of columns 2, 3 and 4;
(b) the maximum strength in the product of that
substance does not exceed the maximum strength (if any) specified in column 2;
and
(c) the medicinal product is sold or
supplied –
(i) if a pharmaceutical
form or a route of administration is specified in column 3, in such
pharmaceutical form, and for administration only by such route, as may be so
specified,
(ii) if
a use is specified in column 3, in a container or package labelled (in either
case) to show a use so specified to which the medicinal product is to be put
but no use not so specified,
(iii) if a
maximum dose is specified in column 4, in a container or package labelled (in
either case) to show a maximum dose not exceeding that specified, and
(iv) if a
maximum daily dose is specified in column 4, in a container or package labelled
(in either case) to show a maximum daily dose not exceeding that specified.
(2) Notwithstanding
Article 2 of this Order, a medicinal product shall not be a prescription
only medicine by reason that it is a controlled drug, where –
(a) it contains not more than one of the
substances specified in column 1 of Part 2 of Schedule 1 to this Order
and no other controlled drug;
(b) it contains that substance at a strength
that does not exceed the maximum strength specified in column 2; and
(c) it is sold or supplied –
(i) in such
pharmaceutical form as may be specified in column 3, and
(ii) in
or from a container or package labelled (in either case) to show a maximum dose
not exceeding that specified in column 4.
(4) Notwithstanding
Article 2, a medicinal product specified in Part 3 or 4 of Schedule 1
shall not be a prescription only medicine.
4 New
medicinal products
For the purposes of Article 58(2)(a)
of the Law their duration shall be a period of 5 years.
5 Appropriate
practitioner[4]
(1) For the purposes of
Article 57(1), the following are appropriate practitioners –
(a) doctors;
(b) dentists;
(c) veterinary
surgeons;
(d) nurse
independent prescribers;
(e) optometrist
independent prescribers, but only in relation to a medicinal product that is
not a controlled drug and that is not for parenteral administration;
(f) paramedic
independent prescribers, but only in relation to a medicinal product that does
not contain a controlled drug other than –
(i) Codeine,
(ii) Fentanyl,
(iii) Midazolam,
or
(iv) Morphine;
and
(g) pharmacist
independent prescribers;
(h) physiotherapist
independent prescribers, but only in relation to a medicinal product that does
not contain a controlled drug other than –
(i) Dihydrocodeine,
(ii) Fentanyl,
(iii) Morphine,
(iv) Oxycodone,
or
(v) Temazepam;
(i) podiatrist
independent prescribers, but only in relation to a medicinal product that does
not contain a controlled drug other than Dihydrocodeine or Temazepam;
(j) supplementary
prescribers;
(k) therapeutic
radiographer independent prescribers, but only in relation to a medicinal
product that does not contain a controlled drug other than –
(i) Codeine,
(ii) Fentanyl,
(iii) Midazolam,
(iv) Morphine,
(v) Oxycodone,
(vi) Temazepam,
or
(vii) Tramadol.
(2) In this Article, a
reference to the following occupations is taken to be a reference to a person
registered in respect of that occupation under the Health Care (Registration)
(Jersey) Law 1995 –
(a) nurse
independent prescriber;
(b) optometrist
independent prescriber;
(c) paramedic
independent prescriber;
(d) pharmacist
independent prescriber;
(e) physiotherapist
independent prescriber;
(f) podiatrist
independent prescriber;
(g) therapeutic
radiographer independent prescriber.
6 Conditions
for prescriptions relating to sale and supply[5]
(1) For
the purposes of Article 57(2)(a) of the Law (read with paragraph (4)
of that Article), a prescription only medicine shall not be taken to be sold or
supplied in accordance with a prescription given by an appropriate practitioner
unless the conditions in paragraph (2) of this Article are fulfilled.
(2) The
conditions to which paragraph (1) refers are –
(a) the prescription shall be written in ink or
otherwise so as to be indelible, unless it is a health prescription that is not
for a controlled drug specified in any of Schedules 1, 2 and 3 to the Misuse
of Drugs (General Provisions) (Jersey) Order 1989, in which case it may be
written using carbon paper or similar material;
(b) the prescription shall be signed in ink,
with his or her own name, by the practitioner giving it;
(c) the prescription shall contain the following
information –
(i) the address of
the practitioner giving it,
(ii) the
appropriate date,
(iii) by
virtue of which of the paragraphs of Article 5 the practitioner giving it
is an appropriate practitioner,
(iv) where
the practitioner giving it is an appropriate practitioner other than a
veterinary surgeon, the name and address of the person for whose treatment it
is given and (if that person is under 12) his or her age, and
(v) where the practitioner
giving it is a veterinary surgeon, the name and address of the person to whom
the prescription only medicine is to be delivered, and a declaration by that
veterinary surgeon that the prescription only medicine is prescribed for an
animal or herd under his or her care;
(ca) in the case of a prescription given by a
supplementary prescriber, the supplementary prescriber –
(i) has given the
prescription in accordance with the terms of a clinical management plan
containing the information specified in Schedule 4, such plan relating to
an individual patient and to which the following are parties –
(A) the
patient,
(B) the
patient’s doctor or dentist, and
(C) the
supplementary prescriber, and
(ii) has
access to the health records of the patient to whom the clinical management
plan relates to the extent that such records are used by the doctor or dentist
who is a party to the plan;
(d) the prescription shall not be dispensed
after the end of the period of 6 months from the appropriate date unless it is
a repeatable prescription, in which case it shall not be dispensed for the
first time after the end of that period or otherwise than in accordance with
the direction contained in the repeatable prescription; and
(e) in the case of a repeatable prescription
that does not specify the number of times that it may be dispensed, the
prescription shall not be dispensed on more than 2 occasions unless it is a
prescription for oral contraceptives, in which case it may be dispensed 6 times
before the end of the period of 6 months from the appropriate date.[6]
(3) The
restrictions in Article 57(2)(a) of the Law shall not apply to a sale or
supply of a prescription only medicine that, by reason only that a condition in
paragraph (2) of this Article is not fulfilled, is not in accordance with
a prescription given by an appropriate practitioner, where the person selling
or supplying the prescription only medicine, having exercised all due
diligence, believes on reasonable grounds that that condition is fulfilled in
relation to that sale or supply.
(4) In
paragraph (2), the “appropriate date” means –
(a) in the case of a health
prescription –
(i) the date on which
it was signed by the practitioner by whom it was given, or
(ii) if
it also contains a date indicated by him or her as being the date before which
it shall not be dispensed, the later of the 2 dates; and
(b) in every other case, the date on which the
prescription was signed by the practitioner by whom it was given.
6A Conditions for
prescriptions – administration[7]
(1) For
the purposes of Article 57(2)(b) of the Law (read with paragraph (4)
of that Article), a prescription only medicine shall not be taken to be
administered by a supplementary prescriber or by a person acting in accordance
with the directions of a supplementary prescriber unless the conditions in paragraph (2)
are met.
(2) Those
conditions are that –
(a) the supplementary prescriber is acting in
accordance with the terms of a clinical management plan containing the
information specified in Schedule 4, such plan relating to an individual
patient to which the following are parties –
(i) the patient,
(ii) the
patient’s doctor or dentist, and
(iii) the
supplementary prescriber; and
(b) the supplementary prescriber has access to the
health records of the patient to whom the clinical management plan relates to
the extent that such records are used by the doctor or dentist who is a party
to the plan.
7 Exemption
for highly diluted medicinal products
The restrictions in Article 57(2)
of the Law shall not apply to the sale, supply or administration of a medicinal
product that is not for parenteral administration and only consists of or only
contains one or more of the substances specified in column 1 of Part 1 or
2 of Schedule 1 to this Order, where –
(a) each
unit preparation has been diluted to at least one part in a million (6x), and
the person selling, supplying or administering the medicinal product has been
requested by or on behalf of a particular person and in that person’s
presence to use his or her own judgment as to the treatment required; or
(b) each
such unit preparation has been diluted to at least one part in a million
million (6c).
8 Exemptions
for specified categories of persons
(1) The
restrictions in Article 57(2)(a) of the Law shall not apply –
(a) to the sale or supply by a person specified
in column 1 of Part 1 of Schedule 2 to this Order; or
(b) to the supply by a person specified in
column 1 of Part 2 of Schedule 2 to this Order,
of a prescription only
medicine specified in column 2 of Part 1 or 2 of that Schedule in relation
to that person, where the conditions in the corresponding paragraph in column 3
of that Part are fulfilled.
(2) The
restriction in Article 57(2)(b) of the Law shall not apply to the
administration by a person specified in column 1 of Part 3 of Schedule 2
to this Order of a prescription only medicine for parenteral administration
specified in column 2 of that Part in relation to that person, where the
conditions in the corresponding paragraph in column 3 of that Part are
fulfilled.
9 Exemption
for emergency sale or supply
(1) The
restrictions in Article 57(2)(a) of the Law shall not apply to the sale or
supply of a prescription only medicine by a person who is lawfully conducting a
retail pharmacy business, where the conditions in paragraph (2) of this Article
or the alternative conditions in paragraph (3) of this Article are
fulfilled.
(2) The
conditions to which paragraph (1) of this Article refers are –
(a) the pharmacist by or under whose supervision
the prescription only medicine is to be sold or supplied is satisfied that the
sale or supply has been requested by a doctor who, by reason of any emergency,
is unable to furnish a prescription immediately;
(b) the doctor has undertaken to furnish the person
lawfully conducting the retail pharmacy business with a prescription within 72
hours;
(c) the prescription only medicine is sold or
supplied in accordance with the directions of the doctor requesting it;
(d) the prescription only medicine is not a
controlled drug specified in any of Schedules 1, 2 and 3 to the Misuse of
Drugs (General Provisions) (Jersey) Order 1989; and
(e) an entry is made in the register to be kept
under Article 3(1) of the Medicines
(Sale and Supply) (Miscellaneous Provisions) (Jersey) Order 1997, within the appropriate time specified in that Article, of the
information in paragraph 1 of Schedule 2 to that Order.
(3) The
alternative conditions to which paragraph (1) of this Article refers
are –
(a) the pharmacist by or under whose supervision
the prescription only medicine is to be sold or supplied has interviewed the person
requesting a prescription only medicine and is satisfied –
(i) that there is an
immediate need for that prescription only medicine to be sold or supplied and
that it is impracticable in the circumstances to obtain a prescription without
undue delay,
(ii) that
treatment with that prescription only medicine has been prescribed on a
previous occasion by a doctor for the person requesting it from the pharmacist,
or (as far as the pharmacist is reasonably able to ascertain) has been lawfully
prescribed on a previous occasion by a medical practitioner outside Jersey for
the person requesting it from the pharmacist, and
(iii) as to
the dose which, in the circumstances, it would be appropriate for that person
to take;
(b) the prescription only medicine –
(i) will be sold or
supplied in no greater quantity than will provide 5 days’ treatment,
(ii) is
a preparation of insulin, an aerosol for the relief of asthma, an ointment or a
cream, and has been made up for sale in a container elsewhere than at the place
of sale or supply, and is the smallest pack that the pharmacist has available
for sale or supply,
(iii) is an
oral contraceptive and is sufficient, but no more than sufficient, for a full
cycle, or
(iv) is an
antibiotic for oral administration in liquid form, and is the smallest quantity
that will provide a full course of treatment;
(c) the prescription only medicine does not
consist of or contain a substance specified in Schedule 3 to this Order
and is not a controlled drug specified in any of the Schedules to the Misuse of
Drugs (General Provisions) (Jersey) Order 1989;
(d) an entry is made in the register to be kept
under Article 3(1) of the Medicines
(Sale and Supply) (Miscellaneous Provisions) (Jersey) Order 1997 within the appropriate time specified in that Article, of the
information in paragraph 3 of Schedule 2 to that Order; and
(e) the container or package of the prescription
only medicine is labelled so as to show –
(i) the date on which
the prescription only medicine is sold or supplied,
(ii) the
name, quantity and (unless it is apparent from the name) the pharmaceutical form
and strength of the prescription only medicine,
(iii) the
name of the person requesting the prescription only medicine,
(iv) the
name and address of the registered pharmacy from which the prescription only
medicine is sold or supplied, and
(v) the words
“Emergency Supply”.[8]
(4) The
conditions in paragraph (2)(d) of this Article and in paragraph (3)(c)
of this Article shall not apply where the prescription only
medicine –
(a) consists of or contains phenobarbitone or
phenobarbitone sodium (but no other substance specified in Schedule 3 to
this Order or in any of the Schedules to the Misuse of Drugs (General
Provisions) (Jersey) Order 1989); and
(b) is sold or supplied for use in the treatment
of epilepsy.
10 Exemption for
sale or supply in hospitals or the prison[9]
(1) The
restrictions in Article 57(2)(a) of the Law shall not apply to the sale or
supply of any prescription only medicine –
(a) in the course of the business of a hospital;
or
(b) by a pharmacy to the prison under the terms
of a contract to supply medicinal products for the benefit of prisoners,
in accordance with the
written directions of an appropriate practitioner, other than a supplementary
prescriber, even though those directions do not fulfil the conditions in
Article 6(2) of this Order.
(2) In
the case of directions given by a supplementary prescriber, paragraph (1)
applies except that the condition in Article 6(2)(ca) must be fulfilled as
if the references to a prescription in that sub-paragraph were references to
the directions given by the supplementary prescriber.
11 Exemption for
authorised needle supply services[10]
The restrictions of
Article 57(2)(a) of the Law shall not apply to the supply by a person, for
parenteral administration, of ampoules of sterile water, if the supply is made
by the person in the course of acting on behalf of a service provided by or on
behalf of the States for the purpose of enabling the supply of syringes, and
associated articles, so as to reduce the spread of disease.
12 Exemption
for sale or supply in cases involving another’s default
The restrictions in Article 57(2)(a)
of the Law shall not apply to the sale or supply of a prescription only
medicine by a person who, having exercised all due diligence, believes on
reasonable grounds that the product sold or supplied is not a prescription only
medicine, and it is because of an act or default of another person that the
product is a product to which that sub-paragraph applies.
13 Exemption
in the case of forged prescription
The restrictions in Article 57(2)(a)
of the Law shall not apply to the sale or supply of a prescription only medicine
by a pharmacist in accordance with a forged prescription where the pharmacist,
having exercised all due diligence, believes on reasonable grounds that the
prescription is genuine.
14 Exemption
for parenteral administration to human beings
The restriction in Article 57(2)(b)
of the Law shall not apply to the administration to human beings of any of the
following medicinal products for parenteral administration, namely –
adrenaline
injection BP;
atropine
sulphate injection;
chlorpheniramine
injection;
cobalt edetate injection;
dextrose injection strong B.P.C.;
diphenhydramine
injection;
glucagon
injection;
hydrocortisone
injection;
mepyramine
injection;
naloxone injection;
promethazine hydrochloride
injection;
snake venom antiserum;
sodium nitrite injection;
sodium thiosulphate injection; and
sterile pralidoxime injection,
where it is administered
for the purpose of saving life in an emergency.
15 Exemption
for non-parenteral administration to human beings
The restriction in Article 57(2)(b)
of the Law shall not apply to the administration to human beings of a
prescription only medicine that is not for parenteral administration.
16 Citation
This Order may be cited
as the Medicines (Prescription Only) (Jersey) Order 1997.
SCHEDULE 1
(Articles 1(2),
2(a), 3(1) and 7)
PART 1[11]
PRESCRIPTION ONLY MEDICINES
[Note –
(x) indicates that the entry is to be read
subject to paragraph 1 of the note at the end of Part 1 of Schedule 1
(y) indicates that the entry is to be read
subject to paragraph 2 of the note at the end of Part 1 of Schedule 1]
Prescription Only Medicine
|
Circumstances In Which
Substances Are Not Prescription Only Medicines
|
Column 1
|
Column 2
|
Column 3
|
Column 4
|
Substance
|
Maximum strength
|
Use, pharmaceutical form or route of administration
|
Maximum dose and maximum daily dose
|
Acamprosate
|
|
|
|
Acarbose
|
|
|
|
Acebutolol Hydrochloride
|
|
|
|
Aceclofenac
|
|
|
|
Acemetacin
|
|
|
|
Acetarsol
|
|
|
|
Acetazolamide
|
|
|
|
Acetazolamide Sodium
|
|
|
|
Acetohexamide
|
|
|
|
Acetylcholine Chloride
|
0.2%
|
External
|
|
Acetylcysteine
|
|
|
|
Aciclovir
|
|
|
|
Acipimox
|
|
|
|
Acitretin
|
|
|
|
Aclarubicin Hydrochloride
|
|
|
|
Aconite
|
1.3%
|
External
|
|
Acrivastine
|
|
|
|
Acrosoxacin
|
|
|
|
Actinomycin C
|
|
|
|
Actinomycin D
|
|
|
|
Adapalene
|
|
|
|
Adenosine
|
|
|
|
Adrenaline
|
|
(1) By inhaler
(2) External
|
|
Adrenaline Acid Tartrate
|
|
(1) By inhaler
(2) External
|
|
Adrenaline Hydrochloride
|
|
(1) By inhaler
(2) External
|
|
Adrenocortical Extract
|
|
|
|
Aclofenac
|
|
|
|
Albendazole
|
|
|
|
Alclometasone Dipropionate
|
|
|
|
Alcuronium Chloride
|
|
|
|
Aldesleukin
|
|
|
|
Aldosterone
|
|
|
|
Alendronate Sodium
|
|
|
|
Alfacalcidol
|
|
|
|
Alfuzosin Hydrochloride
|
|
|
|
Allergen Extracts
|
|
|
|
Allopurinol
|
|
|
|
Allyloestrenol
|
|
|
|
Aloxiprin
|
|
|
|
Alphadolone Acetate
|
|
|
|
Alphaxalone
|
|
|
|
Alprenolol
|
|
|
|
Alprenolol Hydrochloride
|
|
|
|
Alprostadil
|
|
|
|
Alseroxylon
|
|
|
|
Altretamine
|
|
|
|
Amantadine Hydrochloride
|
|
|
|
Ambenonium Chloride
|
|
|
|
Ambutonium Bromide
|
|
|
|
Amcinonide
|
|
|
|
Ametazole Hydrochloride
|
|
|
|
Amethocaine
|
|
Any use (except local ophthalmic use)
|
|
Amethocaine Gentisate
|
|
Any use (except local ophthalmic use)
|
|
Amethocaine Hydrochloride
|
|
Any use (except local ophthalmic use)
|
|
Amikacin Sulphate
|
|
|
|
Amiloride Hydrochloride
|
|
|
|
Aminocaproic Acid
|
|
|
|
Aminoglutethimide
|
|
|
|
Aminopterin Sodium
|
|
|
|
Amiodarone Hydrochloride
|
|
|
|
Amiphenazole Hydrochloride
|
|
|
|
Amisulpride
|
|
|
|
Amitriptyline
|
|
|
|
Amitriptyline Embonate
|
|
|
|
Amitriptyline Hydrochloride
|
|
|
|
Amlodipine Besylate
|
|
|
|
Ammonium Bromide
|
|
|
|
Amodiaquine Hydrochloride
|
|
|
|
Amorolfine Hydrochloride
|
|
|
|
Amoxapine
|
|
|
|
Amoxycillin
|
|
|
|
Amoxycillin Sodium
|
|
|
|
Amoxycillin Trihydrate
|
|
|
|
Amphomycin Calcium
|
|
|
|
Amphotericin
|
|
|
|
Ampicillin
|
|
|
|
Ampicillin Sodium
|
|
|
|
Ampicillin Trihydrate
|
|
|
|
Amsacrine
|
|
|
|
Amygdalin
|
|
|
|
Amyl Nitrite
|
|
|
|
Amylocaine Hydrochloride
|
|
Any use (except local ophthalmic use)
|
|
Anastrazole
|
|
|
|
Ancrod
|
|
|
|
Androsterone
|
|
|
|
Angiotensin Amide
|
|
|
|
Anistreplase
|
|
|
|
Anterior Pituitary Extract
|
|
|
|
Antimony Barium Tartrate
|
|
|
|
Antimony Dimercaptosuccinate
|
|
|
|
Antimony Lithium Thiomalate
|
|
|
|
Antimony Pentasulphide
|
|
|
|
Antimony Potassium Tartrate
|
|
|
|
Antimony Sodium Tartrate
|
|
|
|
Antimony Sodium Thiogycollate
|
|
|
|
Antimony Sulphate
|
|
|
|
Antimony Trichloride
|
|
|
|
Antimony Trioxide
|
|
|
|
Antimony Trisulphide
|
|
|
|
Apiol
|
|
|
|
Apomorphine
|
|
|
|
Apomorphine Hydrochloride
|
|
|
|
Apraclonidine Hydrochloride
|
|
|
|
Aprotinin
|
|
|
|
Arecoline Hydrobromide
|
|
|
|
Argipressin
|
|
|
|
Aristolochia
|
|
|
|
Aristolochia Clematitis
|
|
|
|
Aristolochia Contorta
|
|
|
|
Aristolochia Debelis
|
|
|
|
Aristolochia Fang-chi
|
|
|
|
Aristolochia Manshuriensis
|
|
|
|
Aristolochia Serpentaria
|
|
|
|
Arsenic
|
|
|
|
Arsenic Triiodide
|
|
|
|
Arsenic Trioxide
|
|
|
|
Arsphenamine
|
|
|
|
Aspirin
|
|
Any form (except non-effervescent tablets or capsules)
|
|
Astemizole
|
|
|
|
Atenolol
|
|
|
|
Atorvastatin
|
|
|
|
Atorvastatin Calcium
|
|
|
|
Atovaquone
|
|
|
|
Atracurium Besylate
|
|
|
|
Atropine
|
|
(1) Internal:
(a) by inhaler
(b) otherwise than by inhaler
|
(b) 300 mcg (MD) 1 mg (MDD)(x)
|
|
|
(2) External (except local ophthalmic use)
|
|
Atropine Methobromide
|
|
(1) Internal:
(a) by inhaler
(b) otherwise than by inhaler
|
(b) 400 mcg (MD) 1.3mg (MDD)(x)
|
|
|
(2) External (except local ophthalmic use)
|
|
Atropine Methonitrate
|
|
Internal:
(a) by inhaler
(b) otherwise than by inhaler
|
(b) 400 mcg (MD) 1.3 mg (MDD)(x)
|
Atropine Oxide Hydrochloride
|
|
(1) Internal:
(a) by inhaler
(b) otherwise than by inhaler
|
(b) 360mcg (MD) 1.2mg (MDD)(x)
|
|
|
(2) External (except local opthalmic use)
|
|
Atropine Sulphate
|
|
(1) Internal:
(a) by inhaler
(b) otherwise than by inhaler
|
(b) 360 mcg (MD) 1.2 mg (MD)(x)
|
|
|
(2) External (except local ophthalmic use)
|
|
Auranofin
|
|
|
|
Azapropazone
|
|
|
|
Azathioprine
|
|
|
|
Azathioprine Sodium
|
|
|
|
Azelaic Acid
|
|
|
|
Azelastine Hydrochloride
|
|
|
|
Azidocillin Potassium
|
|
|
|
Azithromycin
|
|
|
|
Azlocillin Sodium
|
|
|
|
Aztreonam
|
|
|
|
Bacampicillin Hydrochloride
|
|
|
|
Bacitracin
|
|
|
|
Bacitracin Methylene Disalicylate
|
|
|
|
Bacitracin Zinc
|
|
|
|
Baclofen
|
|
|
|
Balsalazide Sodium
|
|
|
|
Bambuterol Hydrochloride
|
|
|
|
Barium Carbonate
|
|
|
|
Barium Chloride
|
|
|
|
Barium Sulphide
|
|
|
|
Beclamide
|
|
|
|
Beclomethasone
|
|
|
|
Beclomethasone Diproprionate
|
|
|
|
Belladonna Herb
|
|
(1) Internal
(2) External
|
(1) 1 mg of the alkaloids (MDD)
|
Belladonna Root
|
|
(1) Internal
(2) External
|
(1) 1 mg of the alkaloids (MDD)
|
Bemegride
|
|
|
|
Bemegride Sodium
|
|
|
|
Benapryzine Hydrochloride
|
|
|
|
Bendrofluazide
|
|
|
|
Benethamine Penicillin
|
|
|
|
Benoxaprofen
|
|
|
|
Benperidol
|
|
|
|
Benserazide
|
|
|
|
Benserazide Hydrochloride
|
|
|
|
Bentiromide
|
|
|
|
Benzathine Penicillin
|
|
|
|
Benzbromarone
|
|
|
|
Benzhexol Hydrochloride
|
|
|
|
Benzilonium Bromide
|
|
|
|
Benzocaine
|
|
Any use (except local ophthalmic use)
|
|
Benzoctamine Hydrochloride
|
|
|
|
Benzoyl Peroxide
|
10.0%
|
External
|
|
N-Benzoyl Sulphanilamide
|
|
|
|
Benzquinamide
|
|
|
|
Benzquinamide Hydrochloride
|
|
|
|
Benzthiazide
|
|
|
|
Benztropine Mesylate
|
|
|
|
Benzylpenicillin Calcium
|
|
|
|
Benzylpenicillin Potassium
|
|
|
|
Benzylpenicillin Sodium
|
|
|
|
Beractant
|
|
|
|
Betahistine Hydrochloride
|
|
|
|
Betamethasone
|
|
|
|
Betamethasone Adamantoate
|
|
|
|
Betamethasone Benzoate
|
|
|
|
Betamethasone Dipropionate
|
|
|
|
Betamethasone Sodium Phosphate
|
|
|
|
Betamethasone Valerate
|
|
|
|
Betaxolol Hydrochloride
|
|
|
|
Bethanechol Chloride
|
|
|
|
Bethanidine Sulphate
|
|
|
|
Bezafibrate
|
|
|
|
Bicalutamide
|
|
|
|
Biperiden Hydrochloride
|
|
|
|
Biperiden Lactate
|
|
|
|
Bismuth Glycollylarsanilate
|
|
|
|
Bisoprolol Fumarate
|
|
|
|
Bleomycin
|
|
|
|
Bleomycin Sulphate
|
|
|
|
Bretylium Tosylate
|
|
|
|
Brimonidine Tartrate
|
|
|
|
Bromhexine Hydrochloride
|
|
|
|
Bromocriptine Mesylate
|
|
|
|
Bromperidol
|
|
|
|
Bromvaletone
|
|
|
|
Brotizolam
|
|
|
|
Budesonide
|
|
|
|
Bufexamac
|
|
|
|
Bumetanide
|
|
|
|
Buphenine Hydrochloride
|
|
|
6 mg (MD)
18 mg (MDD)
|
Bupivacaine
|
|
Any use (except local ophthalmic use)
|
|
Bupivacaine Hydrochloride
|
|
Any use (except local ophthalmic use)
|
|
Buserelin Acetate
|
|
|
|
Buspirone Hydrochloride
|
|
|
|
Busulphan
|
|
|
|
Butacaine Sulphate
|
|
Any use (except local ophthalmic use)
|
|
Butorphenol Tartrate
|
|
|
|
Butriptyline Hydrochloride
|
|
|
|
Cabergoline
|
|
|
|
Calcipotriol
|
|
|
|
Calcipotriol Hydrate
|
|
|
|
Calcitonin
|
|
|
|
Calcitriol
|
|
|
|
Calcium Amphomycin
|
|
|
|
Calcium Benzamidosalicylate
|
|
|
|
Calcium Bromide
|
|
|
|
Calcium Bromidolactobionate
|
|
|
|
Calcium Carbimide
|
|
|
|
Calcium Folinate
|
|
|
|
Calcium Metrizoate
|
|
|
|
Calcium Sulphaloxate
|
|
|
|
Candesartan Cilexetil
|
|
|
|
Candicidin
|
|
|
|
Canrenoic Acid
|
|
|
|
Cantharidin
|
0.01%
|
External
|
|
Capreomycin Sulphate
|
|
|
|
Captopril
|
|
|
|
Carbachol
|
|
|
|
Carbamazepine
|
|
|
|
Carbaryl
|
|
|
|
Carbasalate Calcium
|
|
|
|
Carbenicillin Sodium
|
|
|
|
Carbenoxolone Sodium
|
|
(1) Pellet
|
(1) 5 mg (MD)
25 mg (MDD)
|
|
(2) 2.0%
|
(2) Gel
|
|
Carbidopa
|
|
|
|
Carbimazole
|
|
|
|
Carbocisteine
|
|
|
|
Carbon Tetrachloride
|
|
|
|
Carboplatin
|
|
|
|
Carboprost Trometamol
|
|
|
|
Carbuterol Hydrochloride
|
|
|
|
Carfecillin Sodium
|
|
|
|
Carindacillin Sodium
|
|
|
|
Carisoprodol
|
|
|
|
Carmustine
|
|
|
|
Carperidine
|
|
|
|
Carteolol Hydrochloride
|
|
|
|
Cefaclor
|
|
|
|
Cefadroxil
|
|
|
|
Cefazedone Sodium
|
|
|
|
Cefdinir
|
|
|
|
Cefixime
|
|
|
|
Cefodizime Sodium
|
|
|
|
Cefotaxime Sodium
|
|
|
|
Cefoxitin Sodium
|
|
|
|
Cefpodoxime Proxetil
|
|
|
|
Cefprozil
|
|
|
|
Cefsulodin Sodium
|
|
|
|
Ceftazidime
|
|
|
|
Ceftizoxime Sodium
|
|
|
|
Ceftriaxone Sodium
|
|
|
|
Cefuroxime Axetil
|
|
|
|
Cefuroxime Sodium
|
|
|
|
Celiprolol Hydrochloride
|
|
|
|
Cephalexin
|
|
|
|
Cephalexin Sodium
|
|
|
|
Cephaloridine
|
|
|
|
Cephalothin Sodium
|
|
|
|
Cephamandole Nafate
|
|
|
|
Cephazolin Sodium
|
|
|
|
Cephradine
|
|
|
|
Cerium Oxalate
|
|
|
|
Cerivastatin
|
|
|
|
Cerivastatin Sodium
|
|
|
|
Ceruletide Diethylamine
|
|
|
|
Cetirizine
|
|
|
|
Chenodeoxycholic Acid
|
|
|
|
Chloral Hydrate
|
|
External
|
|
Chlorambucil
|
|
|
|
Chloramphenicol
|
|
|
|
Chloramphenicol Cinnamate
|
|
|
|
Chloramphenicol Palmitate
|
|
|
|
Chloramphenicol Sodium Succinate
|
|
|
|
Chlorhexadol
|
|
|
|
Chlormadinone Acetate
|
|
|
|
Chlormerodrin
|
|
|
|
Chlormethiazole
|
|
|
|
Chlormethiazole Edisylate
|
|
|
|
Chlormezanone
|
|
|
|
Chloroform
|
(1) 5.0%
|
(1) Internal
(2) External
|
|
Chloroquine Phosphate
|
|
Prophylaxis of malaria
|
|
Chloroquine Sulphate
|
|
Prophylaxis of malaria
|
|
Chlorothiazide
|
|
|
|
Chlorotrianisene
|
|
|
|
Chlorphenoxamine Hydrochloride
|
|
|
|
Chlorpromazine
|
|
|
|
Chlorpromazine Embonate
|
|
|
|
Chlorpromazine Hydrochloride
|
|
|
|
Chlorpropamide
|
|
|
|
Chlorprothixene
|
|
|
|
Chlorprothixene Hydrochloride
|
|
|
|
Chlortetracycline
|
|
|
|
Chlortetracycline Calcium
|
|
|
|
Chlortetracycline Hydrochloride
|
|
|
|
Chlorthalidone
|
|
|
|
Chlorzoxazone
|
|
|
|
Cholestyramine
|
|
|
|
Chorionic Gonadotrophin
|
|
|
|
Ciclacillin
|
|
|
|
Ciclobendazole
|
|
|
|
Cidofovir
|
|
|
|
Cilastatin Sodium
|
|
|
|
Cilazapril
|
|
|
|
Cimetidine
|
|
|
|
Cimetidine Hydrochloride
|
|
|
|
Cinchocaine
|
3.0%
|
Any use (except local ophthalmic use)
|
|
Cinchocaine Hydrochloride
|
Equivalent of 3.0% of Cinchocaine
|
Any use (except local ophthalmic use)
|
|
Cinchophen
|
|
|
|
Cinoxacin
|
|
|
|
Ciprofibrate
|
|
|
|
Ciprofloxacin
|
|
|
|
Ciprofloxacin Hydrochloride
|
|
|
|
Cisapride
|
|
|
|
Cisplatin
|
|
|
|
Citalopram Hydrobromide
|
|
|
|
Clarithromycin
|
|
|
|
Clavulanic Acid
|
|
|
|
Clenbuterol Hydrochloride
|
|
|
|
Clidinium Bromide
|
|
|
|
Clindamycin
|
|
|
|
Clindamycin Hydrochloride
|
|
|
|
Clindamycin Palmitate Hydrochloride
|
|
|
|
Clindamycin Phosphate
|
|
|
|
Clioquinol
|
(1) 35 mg
|
(1) Treatment of mouth ulcers
(2) External (except treatment of mouth ulcers)
|
(1) 350 mg (MDD)
|
Clobetasol Propionate
|
|
|
|
Clobetasone Butyrate
|
|
|
|
Clofazimine
|
|
|
|
Clofibrate
|
|
|
|
Clomiphene Citrate
|
|
|
|
Clomipramine
|
|
|
|
Clomipramine Hydrochloride
|
|
|
|
Clomocycline
|
|
|
|
Clomocycline Sodium
|
|
|
|
Clonidine
|
|
|
|
Clonidine Hydrochloride
|
|
|
|
Clopamide
|
|
|
|
Clopenthixol Decanoate
|
|
|
|
Clopenthixol Hydrochloride
|
|
|
|
Clorexolone
|
|
|
|
Clostebol Acetate
|
|
|
|
Clotrimazole
|
|
External but, in the case of vaginal use, only for the treatment
of vaginal candidiasis
|
|
Cloxacillin Benzathine
|
|
|
|
Cloxacillin Sodium
|
|
|
|
Clozapine
|
|
|
|
Cocculus Indicus
|
|
|
|
Co-dergocrine Mesylate
|
|
|
|
Colaspase
|
|
|
|
Colchicine
|
|
|
|
Colestipol Hydrochloride
|
|
|
|
Colfosceril Palmitate
|
|
|
|
Colistin Sulphate
|
|
|
|
Colistin Sulphomethate
|
|
|
|
Colistin Sulphomethate Sodium
|
|
|
|
Coniine
|
|
|
|
Conium Leaf
|
7.0%
|
External
|
|
Corticotrophin
|
|
|
|
Cortisone
|
|
|
|
Cortisone Acetate
|
|
|
|
Co-tetroxazine
|
|
|
|
Co-Trimoxazole
|
|
|
|
Copropamide
|
|
|
|
Crotethamide
|
|
|
|
Croton Oil
|
|
|
|
Croton Seed
|
|
|
|
Curare
|
|
|
|
Cyclofenil
|
|
|
|
Cyclopenthiazide
|
|
|
|
Cyclopentolate Hydrochloride
|
|
|
|
Cyclophosphamide
|
|
|
|
Cycloserine
|
|
|
|
Cyclosporin
|
|
|
|
Cyclothiazide
|
|
|
|
Cyproterone Acetate
|
|
|
|
Cytarabine
|
|
|
|
Cytarabine Hydrochloride
|
|
|
|
Dacarbazine
|
|
|
|
Dalteparin Sodium
|
|
|
|
Danazol
|
|
|
|
Danthron
|
|
|
|
Dantrolene Sodium
|
|
|
|
Dapsone
|
|
|
|
Dapsone Ethane Ortho Sulphonate
|
|
|
|
Daunorubicin Hydrochloride
|
|
|
|
Deanol Bitartrate
|
|
|
26 mg (MDD)
|
Debrisoquine Sulphate
|
|
|
|
Demecarium Bromide
|
|
|
|
Demeclocycline
|
|
|
|
Demeclocycline Calcium
|
|
|
|
Demeclocycline Hydrochloride
|
|
|
|
Deoxycortone Acetate
|
|
|
|
Deoxycortone Pivalate
|
|
|
|
Deptotropine Citrate
|
|
|
|
Dequalinium Chloride
|
(1) 0.25 mg
|
(1) Internal: throat lozenges or throat pastilles
|
|
|
(2) 1.0%
|
(2) External: paint
|
|
Deserpidine
|
|
|
|
Desferrioxamine Mesylate
|
|
|
|
Desflurane
|
|
|
|
Desfluorotriamcinolone
|
|
|
|
Desipramine Hydrochloride
|
|
|
|
Deslanoside
|
|
|
|
Desmopressin
|
|
|
|
Desogestrel
|
|
|
|
Desonide
|
|
|
|
Desoxymethasone
|
|
|
|
Dexamethasone
|
|
|
|
Dexamethasone Acetate
|
|
|
|
Dexamethasone Isonicotinate
|
|
|
|
Dexamethasone Phenylpropionate
|
|
|
|
Dexamethaone Pivalate
|
|
|
|
Dexamethasone Sodium m-Sulphobenzoate
|
|
|
|
Dexamethasone Sodium Phosphate
|
|
|
|
Dexamethasone Troxundate
|
|
|
|
Dexfenfluramine Hydrochloride
|
|
|
|
Dextromethorphan Hydrobromide
|
|
Internal
|
In the case of a controlled release preparation: equivalent of
30 mg of Dextromethor-phan (MD) equivalent of 75 mg of Dextromethor-phan
(MDD)
|
|
|
|
In any other case: equivalent of 15 mg of Dextromethor-phan (MD)
equivalent of 75 mg of Dextromethor-phan (MDD)
|
Dextrothyroxine Sodium
|
|
|
|
Diazoxide
|
|
|
|
Dibenzepin Hydrochloride
|
|
|
|
Dichloralphenazone
|
|
|
|
Dichlorphenamide
|
|
|
|
Diclofenac Diethylammonium
|
|
|
|
Diclofenac Potassium
|
|
|
|
Diclofenac Sodium
|
|
|
|
Dicyclomine Hydrochloride
|
|
|
10 mg (MD) 60 mg (MDD)
|
Didanosine
|
|
|
|
Dienoestrol
|
|
|
|
Diethanolamine Fusidate
|
|
|
|
Diflucortolone Valerate
|
|
|
|
Diflunisal
|
|
|
|
Digitalin
|
|
|
|
Digitalis Leaf
|
|
|
|
Digitalis, Prepared
|
|
|
|
Digitoxin
|
|
|
|
Digoxin
|
|
|
|
Dihydralazine Sulphate
|
|
|
|
Dihydroergotamine Mesylate
|
|
|
|
Dihydrostreptomycin
|
|
|
|
Dihydrostreptomycin Sulphate
|
|
|
|
Diloxanide Furoate
|
|
|
|
Diltiazem Hydrochloride
|
|
|
|
Dimercaprol
|
|
|
|
Dimethisoquin Hydrochloride
|
|
Any use (except local ophthalmic use)
|
|
Dimethisterone
|
|
|
|
Dimethothiazine Mesylate
|
|
|
|
Dimethyl Sulphoxide
|
|
|
|
Dimethyltubocurarine Bromide
|
|
|
|
Dimethyltubocurarine Chloride
|
|
|
|
Dimethyltubocurarine lodide
|
|
|
|
Dinoprost
|
|
|
|
Dinoprost Trometamol
|
|
|
|
Dinoprostone
|
|
|
|
Diphenhydramine Hydrochloride
|
|
All preparations except liquid-filled capsules
|
|
Dipivefrin Hydrochloride
|
|
|
|
Dipyridamole
|
|
|
|
Disodium Etidronate
|
|
|
|
Disopyramide
|
|
|
|
Disopyramide Phosphate
|
|
|
|
Distigmine Bromide
|
|
|
|
Disulfiram
|
|
|
|
Dithranol
|
1.00%
|
|
|
Dobutamine Hydrochloride
|
|
|
|
Dolasetron Mesilate
|
|
|
|
Domperidone
|
|
|
|
Domperidone Maleate
|
|
|
|
Donepezil
|
|
|
|
Donepezil Hydrochloride
|
|
|
|
Dopamine Hydrochloride
|
|
|
|
Dopexamine Hydrochloride
|
|
|
|
Dorzolamide Hydrochloride
|
|
|
|
Dothiepin
|
|
|
|
Dothiepin Hydrochloride
|
|
|
|
Doxapram Hydrochloride
|
|
|
|
Doxazosin Mesylate
|
|
|
|
Doxepin Hydrochloride
|
|
|
|
Doxorubicin
|
|
|
|
Doxorubicin Hydrochloride
|
|
|
|
Doxycycline
|
|
|
|
Doxycycline Calcium Chelate
|
|
|
|
Doxycycline Hydrochloride
|
|
|
|
Droperidol
|
|
|
|
Drostanolone
|
|
|
|
Drostanolone Propionate
|
|
|
|
Dydrogesterone
|
|
|
|
Dyflos
|
|
|
|
Econazole
|
|
External, but in the case of vaginal use, only for the treatment
of vaginal candidiasis
|
|
Econazole Nitrate
|
|
External, but in the case of vaginal use, only for the treatment
of vaginal candidiasis
|
|
Ecothiopate Iodide
|
|
|
|
Edrophonium Chloride
|
|
|
|
Eflornithine Hydrochloride
|
|
|
|
Eformoterol Fumarate
|
|
|
|
Embutramide
|
|
|
|
Emepronium Bromide
|
|
|
|
Emetine
|
1.0%
|
|
|
Emetine Bismuth
|
|
|
|
Iodide
|
|
|
|
Emetine Hydrochloride
|
Equivalent of 1.0% of Emetine
|
|
|
Enalapril Maleate
|
|
|
|
Encephalitis Virus, Tick-borne, Central European
|
|
|
|
Enoxacin
|
|
|
|
Enoxaparin Sodium
|
|
|
|
Enoximone
|
|
|
|
Ephedrine
|
|
(1) Internal (other than nasal sprays or nasal drops)
|
(1) 30 mg (MD) 60 mg (MDD)
|
|
(2) 2.0%
|
(2) Nasal sprays or nasal drops
|
|
|
|
(3) External
|
|
Ephedrine Hydrochloride
|
|
(1) Internal (other than nasal sprays or nasal drops)
|
(1) Equivalent of 30 mg of Ephedrine (MD) Equivalent of 60 mg of
Ephedrine (MDD)
|
|
(2) Equivalent of 2.0% of Ephedrine
|
(2) Nasal sprays or nasal drops
|
|
|
|
(3) External
|
|
Ephedrine Sulphate
|
|
(1) Internal (other than nasal sprays or nasal drops)
|
(1) Equivalent of 30 mg of Ephedrine (MD) Equivalent of 60 mg of
Ephedrine (MDD)
|
|
(2) Equivalent of 2.0% of Ephedrine
|
(2) Nasal sprays or nasal drops
|
|
|
|
(3) External
|
|
Epicillin
|
|
|
|
Epirubicin
|
|
|
|
Epirubicin Hydrochloride
|
|
|
|
Epithiazide
|
|
|
|
Epoetin Alfa
|
|
|
|
Epoetin Beta
|
|
|
|
Epoprostenol Sodium
|
|
|
|
Ergometrine Maleate
|
|
|
|
Ergometrine Tartrate
|
|
|
|
Ergot, Prepared
|
|
|
|
Ergotamine Tartrate
|
|
|
|
Erythromycin
|
|
|
|
Erythromycin Estolate
|
|
|
|
Erythromycin Ethyl Carbonate
|
|
|
|
Erythromycin Ethyl Succinate
|
|
|
|
Erythromycin Lactobionate
|
|
|
|
Erythromycin Phosphate
|
|
|
|
Erythromycin Stearate
|
|
|
|
Erythromycin Thiocyanate
|
|
|
|
Esmolol Hydrochloride
|
|
|
|
Estramustine Phosphate
|
|
|
|
Estramustine Sodium Phosphate
|
|
|
|
Etafedrine Hydrochloride
|
|
|
|
Ethacrynic Acid
|
|
|
|
Ethambutol Hydrochloride
|
|
|
|
Ethamivan
|
|
|
|
Ethamsylate
|
|
|
|
Ethiazide
|
|
|
|
Ethinyl Androstenediol
|
|
|
|
Ethinyloestradiol
|
|
|
|
Ethionamide
|
|
|
|
Ethisterone
|
|
|
|
Ethoglucid
|
|
|
|
Ethoheptazine Citrate
|
|
|
|
Ethopropazine Hydrochloride
|
|
|
|
Ethosuximide
|
|
|
|
Ethotoin
|
|
|
|
Ethyl Biscoumacetate
|
|
|
|
Ethyloestrenol
|
|
|
|
Ethynodiol Diacetate
|
|
|
|
Etodolac
|
|
|
|
Etomidate
|
|
|
|
Etomidate Hydrochloride
|
|
|
|
Etoposide
|
|
|
|
Etretinate
|
|
|
|
Exemestane
|
|
|
|
Famotidine
|
|
|
|
Fazadinium Bromide
|
|
|
|
Felbinac
|
|
|
|
Felodipine
|
|
|
|
Felypressin
|
|
|
|
Fenbufen
|
|
|
|
Fencamfamin Hydrochloride
|
|
|
|
Fenclofenac
|
|
|
|
Fenfluramine Hydrochloride
|
|
|
|
Fenofibrate
|
|
|
|
Fenoprofen
|
|
|
|
Fenoprofen Calcium
|
|
|
|
Fenoterol Hydrobromide
|
|
|
|
Fenticonazole Nitrate
|
|
External use (but, in the case of vaginal use, only for the
treatment of vulvovaginal candidiasis)
|
|
Feprazone
|
|
|
|
Ferrous Arsenate
|
|
|
|
Ferumoxsil
|
|
|
|
Fexofenadine Hydrochloride
|
|
|
|
Filgrastim
|
|
|
|
Finasteride
|
|
|
|
Flavoxate Hydrochloride
|
|
|
|
Flecainide Acetate
|
|
|
|
Flosequinan
|
|
|
|
Fluanisone
|
|
|
|
Flubendazole
|
|
|
|
Fluclorolone Acetonide
|
|
|
|
Flucloxacillin Magnesium
|
|
|
|
Flucloxacillin Sodium
|
|
|
|
Fluconazole
|
|
|
|
Flucylosine
|
|
|
|
Fludrocortisone Acetate
|
|
|
|
Flufenamic Acid
|
|
|
|
Flumazenil
|
|
|
|
Flumethasone
|
|
|
|
Flumethasone Pivalate
|
|
|
|
Flunisolide
|
|
|
|
Fluocinolone Acetonide
|
|
|
|
Fluocinonide
|
|
|
|
Fluocortin Butyl
|
|
|
|
Fluocortolone
|
|
|
|
Fluocortolone Hexanoate
|
|
|
|
Fluocortolone Pivalate
|
|
|
|
Fluorescein Dilaurate
|
|
|
|
Fluorometholone
|
|
|
|
Fluorouracil
|
|
|
|
Fluorouracil Trometamol
|
|
|
|
Fluoxetine Hydrochloride
|
|
|
|
Fluoxymesterone
|
|
|
|
Flupenthixol Decanoate
|
|
|
|
Flupenthixol Hydrochloride
|
|
|
|
Fluperolone Acetate
|
|
|
|
Fluphenazine Decanoate
|
|
|
|
Fluphenazine Enantate
|
|
|
|
Fluphenazine Hydrochloride
|
|
|
|
Fluprednidene Acetate
|
|
|
|
Fluprednisolone
|
|
|
|
Fluprostenol Sodium
|
|
|
|
Flurandrenolone
|
|
|
|
Flurbiprofen
|
8.75 mg
|
throat lozenges
|
43.75 mg (MDD)
|
Flurbiprofen Sodium
|
|
|
|
Fluspirilene
|
|
|
|
Flutamide
|
|
|
|
Fluticasone Propionate
|
|
Aqueous nasal sprays for the treatment of allergic rhinitis in
persons not less than 18 years
|
|
Flutrimazole
|
|
|
|
Fluvastatin Sodium
|
|
|
|
Fluvoxamine Maleate
|
|
|
|
Folic Acid
|
|
|
500 mcg (MDD)
|
Formestane
|
|
|
|
Formocortal
|
|
|
|
Formoterol Fumarate
|
|
|
|
Foscarnet Sodium
|
|
|
|
Fosfestrol Sodium
|
|
|
|
Fosfomycin Trometamol
|
|
|
|
Fosinopril Sodium
|
|
|
|
Framycetin Sulphate
|
|
|
|
Frusemide
|
|
|
|
Furazolidone
|
|
|
|
Fusafungine
|
|
|
|
Fusidic Acid
|
|
|
|
Gabapentin
|
|
|
|
Gadolinium
|
|
|
|
Gadoteridol
|
|
|
|
Gallamine Triethiodide
|
|
|
|
Ganciclovir
|
|
|
|
Ganciclovir Sodium
|
|
|
|
Gelsemine
|
0.1%
|
|
|
Gelsemium
|
|
|
25 mg (MD) 75 mg (MDD)
|
Gemeprost
|
|
|
|
Gemfibrozil
|
|
|
|
Gentamicin
|
|
|
|
Gentamicin Sulphate
|
|
|
|
Gestodene
|
|
|
|
Gestrinone
|
|
|
|
Gestronol
|
|
|
|
Gestronol Hexanoate
|
|
|
|
Glibenclamide
|
|
|
|
Glibornuride
|
|
|
|
Gliclazide
|
|
|
|
Glimepiride
|
|
|
|
Glipizide
|
|
|
|
Gliquidone
|
|
|
|
Glisoxepide
|
|
|
|
Glucagon
|
|
|
|
Glycopyrronium Bromide
|
|
|
1 mg (MD)
2 mg (MDD)
|
Glymidine
|
|
|
|
Gonadorelin
|
|
|
|
Goserelin Acetate
|
|
|
|
Gramicidin
|
0.2%
|
External
|
|
Granisetron Hydrochloride
|
|
|
|
Griseofulvin
|
|
|
|
Growth Hormone
|
|
|
|
Guanethidine Monosulphate
|
|
|
|
Guanfacine Hydrochloride
|
|
|
|
Guanoclor Sulphate
|
|
|
|
Guanoxan Sulphate
|
|
|
|
Halcinonide
|
|
|
|
Halofantrine Hydrochloride
|
|
|
|
Haloperidol
|
|
|
|
Haloperidol Decanoate
|
|
|
|
Heparin
|
|
External
|
|
Heparin Calcium
|
|
External
|
|
Hexachlorophane
|
|
External:
|
|
|
(a) 2.0%
(b) 0.1%
(c) 0.75%
|
(a) soaps
(b) aerosols
(c) preparations other than soaps and aerosols
|
|
Hexamine Phenylcinchoninate
|
|
|
|
Hexobarbitone
|
|
|
|
Hexobarbitone Sodium
|
|
|
|
Hexoestrol
|
|
|
|
Hexoestrol Dipropionate
|
|
|
|
L-Histidine Hydrochloride
|
|
Dietary or nutritive use
|
|
Homatropine
|
|
(1) Internal
|
(1) 0.15 mg (MD) 0.45 mg (MDD)
|
|
|
(2) External (except local ophthalmic use)
|
|
Homatropine Hydrobromide
|
|
|
0.2 mg (MD)
0.6 mg (MDD)
|
Homatropine Methylbromide
|
|
|
2 mg (MD)
6 mg (MDD)
|
Hydralazine Hydrochloride
|
|
|
|
Hydrargaphen
|
|
Local application to skin
|
|
Hydrobromic Acid
|
|
|
|
Hydrochlorothiazide
|
|
|
|
Hydrocortisone
|
|
|
|
Hydrocortisone Acetate
|
|
|
|
Hydrocortisone Butyrate
|
|
|
|
Hydrocortisone Caprylate
|
|
|
|
Hydrocortisone Hydrogen Succinate
|
|
|
|
Hydrocortisone Sodium Phosphate
|
|
|
|
Hydrocortisone Sodium Succinnate
|
|
|
|
Hydrocyanic Acid
|
|
|
|
Hydroflumethiazide
|
|
|
|
Hydroxychloroquine Sulphate
|
|
Prophylaxis of malaria
|
|
Hydroxyprogesterone
|
|
|
|
Hydroxyprogesterone Enanthate
|
|
|
|
Hydroxyprogesterone Hexanoate
|
|
|
|
Hydroxyurea
|
|
|
|
Hydroxyzine Embonate
|
|
|
|
Hydroxyzine Hydrochloride
|
|
|
|
Hyoscine
|
(1) 0.15%
|
(1) Internal
|
|
|
|
(2) External (except local ophthalmic use)
|
|
Hyoscine Butylbromide
|
|
(1) Internal:
(a) by inhaler
|
(MDD) (x)
|
|
|
(2) External
|
|
Hyoscine Hydrobromide
|
|
(1) Internal:
(a) by inhaler
(b) otherwise than by inhaler
|
(b) 300 mcg (MD) 900 mcg (MDD)(x)
|
|
|
(2) External (except local ophthalmic use)
|
|
Hyoscine Methobromide
|
|
(1) Internal:
(a) by inhaler
|
|
|
|
(b) otherwise than by inhaler
|
(b) 2.5 mg (MD) 7.5 mg (MDD)(x)
|
|
|
(2) External
|
|
Hyoscine Methonitrate
|
|
(1) Internal:
(a) by inhaler
|
|
|
|
(b) otherwise than by inhaler
|
(b) 2.5 mg (MD) 7.5 mg (MDD)(x)
|
|
|
(2) External
|
|
Hyoscyamine
|
|
(1) Internal:
(a) by inhaler
|
|
|
|
(b) otherwise than by inhaler
|
(b) 300 mcg (MD)
1 mg (MDD)(x)
|
|
|
(2) External
|
|
|
|
(3) Preparations for the relief of asthma in the form of
cigarettes, smoking mixtures or fumigants which contain Hyoscyamine as an
alkaloid of Stramonium
|
|
Hyoscyamine Hydrobromide
|
|
(1) Internal:
(a) by inhaler
|
|
|
|
(b) otherwise than by inhaler
|
(b) Equiva-lent of 300 mcg of Hyoscyamine (MD) Equi-valent of 1
mg of Hyos-cyamine (MDD)(x)
|
|
|
(2) External
|
|
Hyoscyamine Sulphate
|
|
(1) Internal:
(a) by inhaler
|
|
|
|
(b) otherwise than by inhaler
|
(b) Equiva-lent of 300 mcg of Hyoscyamine (MD) Equivalent of 1
mg of Hyoscyamine (MDD)(x)
|
|
|
(2) External
|
|
Ibuprofen
|
|
|
|
Ibuprofen Lysine
|
|
Rheumatic and muscular pain, pain of non-serious arthritic
conditions, backache, neuralgia, migraine, headache, dental pain,
dysmenorrhoea, feverishness, symptoms of colds and influenza
|
|
|
|
Internal
|
(a) In the case of a prolonged release preparation 600 mg (MD)
1,200 mg (MDD)
|
|
|
|
(b) In any other case 400 mg (MD) 1,200 mg (MDD)
|
Idarubicin Hydrochloride
|
|
|
|
Idoxuridine
|
|
|
|
Ifosfamide
|
|
|
|
Ignatius Bean
|
|
|
|
Imidapril Hydrochloride
|
|
|
|
Imipenem Hydrochloride
|
|
|
|
Imipramine
|
|
|
|
Imipramine Hydrochloride
|
|
|
|
Imipramine Ion Exchange Resin Bound Salt or Complex
|
|
|
|
Indapamide Hemihydrate
|
|
|
|
Indinavir
|
|
|
|
Indomethacin
|
|
|
|
Indomethacin Sodium
|
|
|
|
Indoramin Hydrochloride
|
|
|
|
Indoprofen
|
|
|
|
Inosine Pranobex
|
|
|
|
Insulin
|
|
|
|
Iodamide
|
|
|
|
Iodamide Meglumine
|
|
|
|
Iodamide Sodium
|
|
|
|
Iohexol
|
|
|
|
Iomeprol
|
|
|
|
Iopamidol
|
|
|
|
Iopentol
|
|
|
|
Iothalamic Acid
|
|
|
|
Ioversol
|
|
|
|
Ioxaglic Acid
|
|
|
|
Ipratropium Bromide
|
|
|
|
Iprindole Hydrochloride
|
|
|
|
Iproniazid Phosphate
|
|
|
|
Irbesartan
|
|
|
|
Isoaminile
|
|
|
|
Isoaminile Citrate
|
|
|
|
Isocarboxazid
|
|
|
|
Isoconazole Nitrate
|
|
External, but in the case of vaginal use, only for the treatment
of vaginal candidiasis
|
|
Isoetharine
|
|
|
|
Isoetharine Hydrochloride
|
|
|
|
Isoetharine Mesylate
|
|
|
|
Isoniazid
|
|
|
|
Isoprenaline Hydrochloride
|
|
|
|
Isoprenaline Sulphate
|
|
|
|
Isopropamide Iodide
|
|
|
Equivalent of 2.5 mg of Isoprop-amide ion (MD)
Equivalent of 5.0 mg of Isoprop-amide ion (MDD)
|
Isotretinoin
|
|
|
|
Isradipine
|
|
|
|
Itraconazole
|
|
|
|
Jaborandi
|
|
External
|
|
Kanamycin Acid Sulphate
|
|
|
|
Kanamycin Sulphate
|
|
|
|
Ketamine Hydrochloride
|
|
|
|
Ketoconazole
|
|
|
|
Ketoprofen
|
|
|
|
Ketorolac Trometamol
|
|
|
|
Ketotifen Pumarate
|
|
|
|
Labetalol Hydrochloride
|
|
|
|
Lachesine Chloride
|
|
|
|
Lacidipine
|
|
|
|
Lamivudine
|
|
|
|
Lamotrigine
|
|
|
|
Lanatoside C
|
|
|
|
Lanatoside Complex A, B and C
|
|
|
|
Lanzoprazole
|
|
|
|
Latamoxef Disodium
|
|
|
|
Latanaprost
|
|
|
|
Lercanidipine Hydrochloride
|
|
|
|
Letrozole
|
|
|
|
Levallorphan Tartrate
|
|
|
|
Levobunolol Hydrochloride
|
|
|
|
Levocabastine Hydrochloride
|
|
|
|
Levocarnitine
|
|
For dietary supplementation
|
|
Levodopa
|
|
|
|
Levofloxacin Hemihydrate
|
|
|
|
Levonorgestrel
|
|
|
|
Lidoflazine
|
|
|
|
Lignocaine
|
|
Any use (except local ophthalmic use)
|
|
Lignocaine Hydrochloride
|
|
Any use (except local ophthalmic use)
|
|
Lincomycin
|
|
|
|
Lincomycin Hydrochloride
|
|
|
|
Liothyronine Sodium
|
|
|
|
Lisinopril
|
|
|
|
Lithium Carbonate
|
|
|
Equivalent of 5 mg of Lithium (MD) Equivalent of 15 mg of Lithium
(MDD)
|
Lithium Citrate
|
|
|
|
Lithium Sulphate
|
|
|
Equivalent of 5 mg of Lithium (MD)
Equivalent of 5 mg of Lithium (MDD)
|
Lithium Succinate
|
|
|
|
Lobeline
|
|
(1) Internal
|
(1) 3 mg (MD)
9 mg (MDD)
|
|
|
(2) External
|
|
Lobeline Hydrochloride
|
|
(1) Internal
|
(1) Equiva-lent of 3 mg of Lobeline (MD)
|
|
|
|
Equivalent of 9 mg of Lobeline (MDD)
|
|
|
(2) External
|
|
Lobeline Sulphate
|
|
(1) Internal
|
(1) Equiva-lent of 3 mg of Lobeline (MD) Equivalent of 9 mg of
Lobeline (MDD)
|
|
|
(2) External
|
|
Lodaximide Trometamol
|
equivalent of 0.1% Lodoxamide
|
For the treatment of ocular signs and symptoms of allergic
conjunctivitis, in adults and in children aged 4 years and over
|
|
Lofepramine
|
|
|
|
Lofepramine Hydrochloride
|
|
|
|
Lofexidine Hydrochloride
|
|
|
|
Lomefloxacin Hydrochloride
|
|
|
|
Lornoxicam
|
|
|
|
Lomustine
|
|
|
|
Loperamide Hydrochloride
|
|
Treatment of acute diarrhoea
|
|
Loratidine
|
|
|
|
Losartan Potassium
|
|
|
|
Loxapine Succinate
|
|
|
|
Lung Surfactant Porcine
|
|
|
|
Luteinising Hormone
|
|
|
|
Lymecycline
|
|
|
|
Lynoestrenol
|
|
|
|
Lypressin
|
|
|
|
Lysuride Maleate
|
|
|
|
Mafenide
|
|
|
|
Mafenide Acetate
|
|
|
|
Mafenide Hydrochloride
|
|
|
|
Mafenide Propionate
|
5.0%
|
Eye drops
|
|
Magnesium Fluoride
|
|
|
|
Magnesium Metrizoate
|
|
|
|
Mandragora Autumnalis
|
|
|
|
Mannomustine Hydrochloride
|
|
|
|
Maprotiline Hydrochloride
|
|
|
|
Mebanazine
|
|
|
|
Mebendazole
|
|
|
|
Mebeverine Hydrochloride
|
|
(a) For the symptomatic relief of irritable bowel syndrome
(b) For uses other than the symptomatic relief of irritable
bowel syndrome
|
(a) 135mg (MD) 405mg (MDD)
(b) 100 mg (MD) 300mg (MDD)
|
Mebeverine Pamoate
|
|
|
|
Mebhydrolin
|
|
|
|
Mebhydrolin Napadisylate
|
|
|
|
Mecamylamine Hydrochloride
|
|
|
|
Mecillinam
|
|
|
|
Meclofenoxate Hydrochloride
|
|
|
|
Medigoxin
|
|
|
|
Medrogestone
|
|
|
|
Medroxyprogesterone Acetate
|
|
|
|
Mefenamic Acid
|
|
|
|
Mefloquine Hydrochloride
|
|
|
|
Mefruside
|
|
|
|
Megestrol
|
|
|
|
Megestrol Acetate
|
|
|
|
Meglumine Gadopentetate
|
|
|
|
Meglumine lodoxamate
|
|
|
|
Meglumine loglycamate
|
|
|
|
Meglumine lothalamate
|
|
|
|
Meglumine lotroxate
|
|
|
|
Meglumine loxaglate
|
|
|
|
Meloxicam
|
|
|
|
Melphalan
|
|
|
|
Melphalan Hydrochloride
|
|
|
|
Menotrophin
|
|
|
|
Mepenzolate Bromide
|
|
|
25 mg (MD) 75 mg (MDD)
|
Mephenesin
|
|
|
|
Mephenesin Carbamate
|
|
|
|
Mepivacaine Hydrochloride
|
|
Any use (except local ophthalmic use)
|
|
Meptazinol Hydrochloride
|
|
|
|
Mequitazine
|
|
|
|
Mercaptamine Bitartrate
|
|
|
|
Mercaptopurine
|
|
|
|
Mersalyl
|
|
|
|
Mersalyl Acid
|
|
|
|
Mesalazine
|
|
|
|
Mesna
|
|
|
|
Mesterolone
|
|
|
|
Mestranol
|
|
|
|
Metaraminol Tartrate
|
|
|
|
Metergoline
|
|
|
|
Metformin Hydrochloride
|
|
|
|
Methacycline
|
|
|
|
Methacycline Calcium
|
|
|
|
Methacycline Hydrochloride
|
|
|
|
Methallenoestril
|
|
|
|
Methandienone
|
|
|
|
Methicillin Sodium
|
|
|
|
Methixene
|
|
|
|
Methixene Hydrochloride
|
|
|
|
Methocarbamol
|
|
|
|
Methocidin
|
|
Throat lozenges and throat pastilles
|
|
Methohexitone Sodium
|
|
|
|
Methoin
|
|
|
|
Methoserpidine
|
|
|
|
Methotrexate
|
|
|
|
Methotrexate Sodium
|
|
|
|
Methotrimeprazine
|
|
|
|
Methotrimeprazine Hydrochloride
|
|
|
|
Methotrimeprazine Maleate
|
|
|
|
Methoxamine Hydrochloride
|
0.25%
|
Nasal sprays, or nasal drops, not containing in either case
liquid paraffin as a vehicle
|
|
Methsuximide
|
|
|
|
Methyclothiazide
|
|
|
|
Methyldopa
|
|
|
|
Methyldopa Hydrochloride
|
|
|
|
Methylephedrine Hydrochloride
|
|
|
30 mg (MD)
60 mg (MDD)
|
Methylprednisolone
|
|
|
|
Methylprednisolone Acetate
|
|
|
|
Methylprednisolone Sodium Succinate
|
|
|
|
Methyltestosterone
|
|
|
|
Methylthiouracil
|
|
|
|
Methysergide Maleate
|
|
|
|
Metipranolol
|
|
|
|
Metirosine
|
|
|
|
Metoclopramide Hydrochloride
|
|
|
|
Metolazone
|
|
|
|
Metoloprolol Tartrate
|
|
|
|
Metoprolol Fumarate
|
|
|
|
Metoprolol Succinate
|
|
|
|
Metronidazole
|
|
|
|
Metronidazole Benzoate
|
|
|
|
Metyrapone
|
|
|
|
Mexiletine Hydrochloride
|
|
|
|
Mezlocillin Sodium
|
|
|
|
Mianserin Hydrochloride
|
|
|
|
Mibefradil Dihydrochloride
|
|
|
|
Miconazole
|
|
External
|
|
Miconazole Nitrate
|
|
External, but in the case of vaginal use, only for the treatment
of vaginal candidiasis
|
|
Mifepristone
|
|
|
|
Miglitol
|
|
|
|
Milrinone
|
|
|
|
Milrinone Lactate
|
|
|
|
Minocycline
|
|
|
|
Minocycline Hydrochloride
|
|
|
|
Minoxidil
|
(1) 2.0%
|
External
|
|
|
(2) 5.0%
|
External, for the treatment of alopecia androgenetica in men who
have attained the age of 18 years but have not attained the age of 65
years
|
|
Mirtazapine
|
|
|
|
Misoprostol
|
|
|
|
Mitobronitol
|
|
|
|
Mitomycin C
|
|
|
|
Mitozantrone Hydrochloride
|
|
|
|
Mivacurium Chloride
|
|
|
|
Mizolastine
|
|
|
|
Moclobemide
|
|
|
|
Modafinil
|
|
|
|
Moexipril Hydrochloride
|
|
|
|
Molgramostim
|
|
|
|
Molindone Hydrochloride
|
|
|
|
Mometasone Furoate
|
|
|
|
Moracizine Hydrochloride
|
|
|
|
Morazone Hydrochloride
|
|
|
|
Moxisylyte Hydrochloride
|
|
|
|
Moxonidine
|
|
|
|
Mupirocin
|
|
|
|
Mupirocin Calcium
|
|
|
|
Mustine Hydrochloride
|
|
|
|
Mycophenolate Mofetil
|
|
|
|
Nabilone
|
|
|
|
Nabumetone
|
|
|
|
Nadolol
|
|
|
|
Nafarelin Acetate
|
|
|
|
Naftidrofuryl Oxalate
|
|
|
|
Naftifine Hydrochloride
|
|
|
|
Nalbuphine Hydrochloride
|
|
|
|
Nalidixic Acid
|
|
|
|
Nalorphine Hydrobromide
|
|
|
|
Naloxone Hydrochloride
|
|
|
|
Naltrexone Hydrochloride
|
|
|
|
Nandrolone Decanoate
|
|
|
|
Nandrolone Laurate
|
|
|
|
Nandrolone Phenylpropionate
|
|
|
|
Naphazoline Hydrochloride
|
(1) 0.05%
|
(1) Nasal sprays, or nasal drops, not containing in either case
liquid paraffin as a vehicle
|
|
|
(2) 0.015%
|
(2) Eye drops
|
|
Naphazoline Nitrate
|
0.05%
|
Nasal sprays, or nasal drops, not containing in either case
liquid paraffin as a vehicle
|
|
Naproxen
|
|
|
|
Naproxen Sodium
|
|
|
|
Naratriptan Hydrochloride
|
|
|
|
Natamycin
|
|
|
|
Nebivolol Hydrochloride
|
|
|
|
Nedocromil Sodium
|
|
|
|
Nefazadone Hydrochloride
|
|
|
|
Nefopam Hydrochloride
|
|
|
|
Neomycin
|
|
|
|
Neomycin Oleate
|
|
|
|
Neomycin Palmitate
|
|
|
|
Neomycin Sulphate
|
|
|
|
Neomycin Undecanoate
|
|
|
|
Neostigmine Bromide
|
|
|
|
Neostigmine Methylsulphate
|
|
|
|
Netilmicin Sulphate
|
|
|
|
Nicardipine Hydrochloride
|
|
|
|
Nicergoline
|
|
|
|
Niceritrol
|
|
|
|
Nicotinic Acid
|
|
Any use (except for the treatment of hyperlipid-aemia)
|
600 mg (MDD)
|
Nicoumalone
|
|
|
|
Nifedipine
|
|
|
|
Nifenazone
|
|
|
|
Nikethamide
|
|
|
|
Nilutamide
|
|
|
|
Nimodipine
|
|
|
|
Niridazole
|
|
|
|
Nisoldipine
|
|
|
|
Nitrendipine
|
|
|
|
Nitrofurantoin
|
|
|
|
Nitrofurazone
|
|
|
|
Nizatidine
|
|
|
|
Nomifensine Maleate
|
|
|
|
Noradrenaline
|
|
|
|
Noradrenaline Acid Tartrate
|
|
|
|
Norethandrolone
|
|
|
|
Norethisterone
|
|
|
|
Norethisterone Acetate
|
|
|
|
Norethisterone Heptanoate
|
|
|
|
Norethynodrel
|
|
|
|
Norfloxacin
|
|
|
|
Norgestimate
|
|
|
|
Norgestrel
|
|
|
|
Nortriptyline Hydrochloride
|
|
|
|
Noscapine
|
|
|
|
Noscapine Hydrochloride
|
|
|
|
Novobiocin Calcium
|
|
|
|
Novobiocin Sodium
|
|
|
|
Nux Vomica Seed
|
|
|
|
Nystatin
|
|
|
|
Octacosactrin
|
|
|
|
Octreotide
|
|
|
|
Oestradiol
|
|
|
|
Oestradiol Benzoate
|
|
|
|
Oestradiol Cypionate
|
|
|
|
Oestradiol Dipropionate
|
|
|
|
Oestradiol Diundecanoate
|
|
|
|
Oestradiol Enanthate
|
|
|
|
Oestradiol Phenylpropionate
|
|
|
|
Oestradiol Undecanoate
|
|
|
|
Oestradiol Valerate
|
|
|
|
Oestriol
|
|
|
|
Oestriol
Di-Hemi Succinate
|
|
|
|
Oestrogenic Substances, Conjugated
|
|
|
|
Oestrone
|
|
|
|
Ofloxacin
|
|
|
|
Olanzapine
|
|
|
|
Olsalazine Sodium
|
|
|
|
Omeprazole
|
|
|
|
Omeprazole Magnesium
|
|
|
|
Ondansetron
|
|
|
|
Ondansetron Hydrochloride
|
|
|
|
Orciprenaline Sulphate
|
|
|
|
Orphenadrine Citrate
|
|
|
|
Orphenadrine Hydrochloride
|
|
|
|
Ouabain
|
|
|
|
Ovarian
Gland, Dried
|
|
|
|
Oxamniquine
|
|
|
|
Oxandronolone
|
|
|
|
Oxantel Pamoate
|
|
|
|
Oxaprozin
|
|
|
|
Oxatomide
|
|
|
|
Oxedrine Tartrate
|
|
|
|
Oxethazaine
|
|
|
|
Oxidronate Sodium
|
|
|
|
Oxitropium Bromide
|
|
|
|
Oxolinic Acid
|
|
|
|
Oxpentifylline
|
|
|
|
Oxprenolol Hydrochloride
|
|
Any use (except local ophthalmic use)
|
|
Oxybuprocaine Hydrochloride
|
|
|
|
Oxybutynin Hydrochloride
|
|
|
|
Oxymetholone
|
|
|
|
Oxypertine
|
|
|
|
Oxypertine Hydrochloride
|
|
|
|
Oxyphenbutazone
|
|
|
|
Oxyphencyclimine Hydrochloride
|
|
|
|
Oxyphenonium Bromide
|
|
|
5 mg (MD)
15 mg (MDD)
|
Oxytetracycline
|
|
|
|
Oxytetracycline Calcium
|
|
|
|
Oxytetracycline Dihydrate
|
|
|
|
Oxytetracycline Hydrochloride
|
|
|
|
Oxytocin, Natural
|
|
|
|
Oxytocin, Synthetic
|
|
|
|
Pamidronate Disodium
|
|
|
|
Pancreatin
|
(1) 21,000 European Pharmacopoeia units of lipase per capsule
|
|
(1) Capsules
|
|
(2) 25,000 European Pharmacopoeia units of lipase per g
|
|
(2) Powder
|
Pancuronium Bromide
|
|
|
|
Pantoprazole
|
|
|
|
Pantoprazole Sodium
|
|
|
|
Papaverine
|
|
(1) By inhaler
|
|
|
|
(2) Otherwise than by inhaler
|
(2) 50 mg (MD)
150 mg (MDD)
|
Papaverine Hydrochloride
|
|
(1) By inhaler
|
|
|
|
(2) Otherwise than by inhaler
|
(2)
Equivalent of 50 mg of Papaverine (MD)
Equivalent of 150 mg of Papaverine (MDD)
|
Paracetamol
|
|
Any form (except non-effervescent tablets and capsules)
|
|
Paraldehyde
|
|
|
|
Paramethadione
|
|
|
|
Paramethasone Acetate
|
|
|
|
Parathyroid Gland
|
|
|
|
Pargyline Hydrochloride
|
|
|
|
Paroxetine Hydrochloride
|
|
|
|
Pecilocin
|
|
|
|
Penamecillin
|
|
|
|
Penbutolol Sulphate
|
|
|
|
Penciclovir
|
|
|
|
Penicillinamine
|
|
|
|
Penicillinamine Hydrochloride
|
|
|
|
Pentamidine Isethionate
|
|
|
|
Pentamidronate Disodium
|
|
|
|
Penthienate Methobromide
|
|
|
5 mg (MD)
15 mg (MDD)
|
Pentolinium Tartrate
|
|
|
|
Perfluamine
|
|
|
|
Pergolide Mesylate
|
|
|
|
Perhexiline Maleate
|
|
|
|
Perindopril
|
|
|
|
Pericyazine
|
|
|
|
Perindopril Erbumine
|
|
|
|
Perphenazine
|
|
|
|
Phenacetin
|
0.1%
|
|
|
Phenazone
|
|
External
|
|
Phenazone and Caffeine Citrate
|
|
|
|
Phenazone Salicylate
|
|
|
|
Phenbutrazate Hydrochloride
|
|
|
|
Phenelzine Sulphate
|
|
|
|
Phenethicillin Potassium
|
|
|
|
Phenformin Hydrochloride
|
|
|
|
Phenglutarimide Hydrochloride
|
|
|
|
Phenindione
|
|
|
|
Phenolphthalein
|
|
|
|
Phenoxybenzamine Hydrochloride
|
|
|
|
Phenoxymethylpenicillin
|
|
|
|
Phenoxymethylpenicillin Calcium
|
|
|
|
Phenoxymethylpenicillin Potassium
|
|
|
|
Phenprocoumon
|
|
|
|
Phensuximide
|
|
|
|
Phentolamine Hydrochloride
|
|
|
|
Phentolamine Mesylate
|
|
|
|
Phenylbutazone
|
|
|
|
Phenylbutazone Sodium
|
|
|
|
Phenylpropanolamine Hydrochloride
|
|
Internal: (a) all preparations (except controlled release
capsules, nasal sprays or nasal drops)
|
(a) 25 mg (MD)
100 mg (MDD)
|
|
|
(b) controlled release capsules
|
(b) 50 mg (MD)
100 mg (MDD)
|
|
(c) 2.0%
|
(c) nasal sprays or nasal drops
|
|
Phenytoin
|
|
|
|
Phenytoin Sodium
|
|
|
|
Phthalylsulphathiazole
|
|
|
|
Physostigmine
|
|
|
|
Physostigmine Aminoxide Salicylate
|
|
|
|
Physostigmine Salicylate
|
|
|
|
Physostigmine Sulphate
|
|
|
|
Phytomenadine
|
|
Any use except the prevention or treatment of haemorrhagic
disorders
|
|
Picrotoxin
|
|
|
|
Pilocarpine
|
|
|
|
Pilocarpine Hydrochloride
|
|
|
|
Pilocarpine Nitrate
|
|
|
|
Pimozide
|
|
|
|
Pindolol
|
|
|
|
Pipenzolate Bromide
|
|
|
5 mg (MD)
15 mg (MDD)
|
Piperacillin Sodium
|
|
|
|
Piperazine Oestrone Sulphate
|
|
|
|
Piperidolate Hydrochloride
|
|
|
50 mg (MD)
150 mg (MDD)
|
Pipothiazine Palmitate
|
|
|
|
Piracetam
|
|
|
|
Pirbuterol Acetate
|
|
|
|
Pirbuterol Hydrochloride
|
|
|
|
Pirenzepine Dihydrochloride Monohydrate
|
|
|
|
Pirenzepine Hydrochloride
|
|
|
|
Piretamide
|
|
|
|
Piroxicam
|
|
|
|
Piroxicam Beta-Cyclodextrin
|
|
|
|
Pituitary Gland (Whole Dried)
|
|
By inhaler
|
|
Pituitary, Powdered (Posterior Lobe)
|
|
By inhaler
|
|
Pivampicillin Hydrochloride
|
|
|
|
Pivmecillinam
|
|
|
|
Pivmecillinam Hydrochloride
|
|
|
|
Pizotifen
|
|
|
|
Pizotifen Malate
|
|
|
|
Plicamycin
|
|
|
|
Podophyllotoxin
|
|
|
|
Podophyllum
|
|
|
|
Podophyllum Indian
|
|
|
|
Podophyllum Resin
|
20.0%
|
External: ointment or impregnated plaster
|
|
Poldine Methylsulphate
|
|
|
2 mg (MDD)
6 mg (MDD)
|
Polidexide
|
|
|
|
Polymyxin B Sulphate
|
|
|
|
Polyestradiol Phosphate
|
|
|
|
Polythiazide
|
|
|
|
Poppy
Capsule
|
|
|
|
Potassium Arsenite
|
0.0127%
|
|
|
Potassium Bromide
|
|
|
|
Potassium Canrenoate
|
|
|
|
Potassium Clavulanate
|
|
|
|
Potassium Perchlorate
|
|
|
|
Practolol
|
|
|
|
Pralidoxime Chloride
|
|
|
|
Pralidoxime lodide
|
|
|
|
Pralidoxime Mesylate
|
|
|
|
Pramipexole Dihydrochloride
|
|
|
|
Pravastatin Sodium
|
|
|
|
Prazosin Hydrochloride
|
|
|
|
Prednisolone
|
|
|
|
Prednisolone Acetate
|
|
|
|
Prednisolone Butylacetate
|
|
|
|
Prednisolone Hexanoate
|
|
|
|
Prednisolone Pivalate
|
|
|
|
Prednisolone Sodium Phosphate
|
|
|
|
Prednisolone Sodium m-Sulphobenzoate
|
|
|
|
Prednisolone 21-Steaglate
|
|
|
|
Prednisolone m-Sulphobenzoate
|
|
|
|
Prednisone
|
|
|
|
Prednisone Acetate
|
|
|
|
Prenalterol Hydrochloride
|
|
|
|
Prenylamine Lactate
|
|
|
|
Prilocaine Hydrochloride
|
|
Any use (except local ophthalmic use)
|
|
Primidone
|
|
|
|
Probenecid
|
|
|
|
Probucol
|
|
|
|
Procainamide Hydrochloride
|
|
|
|
Procaine Hydrochloride
|
|
Any use (except local ophthalmic use)
|
|
Procaine Penicillin
|
|
|
|
Procarbazine Hydrochloride
|
|
|
|
Prochlorperazine
|
|
|
|
Prochlorperazine Edisylate
|
|
|
|
Prochlorperazine Maleate
|
|
|
|
Prochlorperazine Mesylate
|
|
|
|
Procyclidine Hydrochloride
|
|
|
|
Progesterone
|
|
|
|
Prolactin
|
|
|
|
Proligestone
|
|
|
|
Prolintane Hydrochloride
|
|
|
|
Promazine Embonate
|
|
|
|
Promazine Hydrochloride
|
|
|
|
Propafenone
|
|
|
|
Propafenone Hydrochloride
|
|
|
|
Propanidid
|
|
|
|
Propantheline Bromide
|
|
|
15 mg (MD)
45 mg (MDD)
|
Propiverine Hydrochloride
|
|
|
|
Propofol
|
|
|
|
Propranolol Hydrochloride
|
|
|
|
Propylthiouracil
|
|
|
|
Proquazone
|
|
|
|
Protamine Sulphate
|
|
|
|
Prothionamide
|
|
|
|
Protirelin
|
|
|
|
Protriptyline Hydrochloride
|
|
|
|
Proxymetacaine Hydrochloride
|
|
Any use (except local ophthalmic use)
|
|
Pseudoephedrine Hydrochloride
|
|
Internal
|
In the case of a controlled release preparation:
120 mg
(MD)
180 mg
(MDD)
In any
other case:
60 mg
(MD)
180 mg (MDD)
|
Pseudoephedrine Sulphate
|
|
|
60 mg (MD)
180 mg (MDD)
|
Pyrantel Embonate
|
|
|
|
Pyrantel Tartrate
|
|
|
|
Pyrazinamide
|
|
|
|
Pyridostigmine Bromide
|
|
|
|
Pyrimethamine
|
|
|
|
Quetiapine Fumarate
|
|
|
|
Quinagolide Hydrochloride
|
|
|
|
Quinapril
|
|
|
|
Quinapril Hydrochloride
|
|
|
|
Quinestradol
|
|
|
|
Quinestrol
|
|
|
|
Quinethazone
|
|
|
|
Quinidine
|
|
|
|
Quinidine Bisulphate
|
|
|
|
Quinidine Polygalacturonate
|
|
|
|
Quinidine Sulphate
|
|
|
|
Quinine
|
|
|
100 mg (MD)
300 mg (MDD)
|
Quinine Bisulphate
|
|
|
Equivalent of 100 mg of Quinine (MD)
Equivalent of 300 mg of Quinine (MDD)
|
Quinine Dihydrochloride
|
|
|
Equivalent of 100 mg of Quinine (MD)
Equivalent of 300 mg of Quinine (MDD)
|
Quinine Ethyl Carbonate
|
|
|
Equivalent of 100 mg of Quinine (MD)
Equivalent of 300 mg of Quinine (MDD)
|
Quinine Glycero-phosphate
|
|
|
Equivalent of 100 mg of Quinine (MD)
Equivalent of 300 mg of Quinine (MDD)
|
Quinine Hydrobromide
|
|
|
Equivalent of 100 mg of Quinine (MD)
Equivalent of 300 mg of Quinine (MDD)
|
Quinine Hydrocholride
|
|
|
Equivalent of 100 mg of Quinine (MD)
Equivalent of 300 mg of Quinine (MDD)
|
Quinine Iodobismuthate
|
|
|
Equivalent of 100 mg of Quinine (MD)
Equivalent of 300 mg of Quinine (MDD)
|
Quinine Phenylcinchoninate
|
|
|
Equivalent of 100 mg of Quinine (MD)
Equivalent of 300 mg of Quinine (MDD)
|
Quinine Phosphate
|
|
|
Equivalent of 100 mg of Quinine (MD)
Equivalent of 300 mg of Quinine (MDD)
|
Quinine Salicylate
|
|
|
Equivalent of 100 mg of Quinine (MD)
Equivalent of 300 mg of Quinine (MDD)
|
Quinine Sulphate
|
|
|
Equivalent of 100 mg of Quinine (MD)
Equivalent of 300 mg of Quinine (MDD)
|
Quinine Tannate
|
|
|
Equivalent of 100 mg of Quinine (MD)
Equivalent of 300 mg of Quinine (MDD)
|
Quinine and Urea Hydrochloride
|
|
|
|
Ramipril
|
|
|
|
Ranitidine Bismuth Citrate
|
|
|
|
Ranitidine Hydrochloride
|
|
|
|
Rauwolfia Serpentina
|
|
|
|
Rauwolfia Vomitoria
|
|
|
|
Reboxetine
|
|
|
|
Reboxetine Mesilate
|
|
|
|
Remoxipride Hydrochloride
|
|
|
|
Reproterol Hydrochloride
|
|
|
|
Rescinnamine
|
|
|
|
Reserpine
|
|
|
|
Rifabutin
|
|
|
|
Rifampicin
|
|
|
|
Rifampicin Sodium
|
|
|
|
Rifamycin
|
|
|
|
Rimexolone
|
|
|
|
Rimiterol Hydrobromide
|
|
|
|
Risperidone
|
|
|
|
Ritodrine Hydrochloride
|
|
|
|
Ritonavir
|
|
|
|
Rolitetracycline Nitrate
|
|
|
|
Ropinorole Hydrochloride
|
|
|
|
Sabadilla
|
|
|
|
Salbutamol
|
|
|
|
Salbutamol Sulphate
|
|
|
|
Salcatonin
|
|
|
|
Salcatonin Hydrated Polyacetate
|
|
|
|
Salmefamol
|
|
|
|
Salmeterol Hydroxynaphthoate
|
|
|
|
Salsalate
|
|
|
|
Saquinavir
|
|
|
|
Saralasin Acetate
|
|
|
|
Selegiline Hydrochloride
|
|
|
|
Sera and Antisera –
|
|
|
|
Botulin Antitoxin
|
|
|
|
Diphtheria Antitoxin
|
|
|
|
Gas-gangrene Antitoxin (Oedematiens)
|
|
|
|
Gas-gangrene Antitoxin (Perfringens)
|
|
|
|
Gas-gangrene Antitoxin (Septicum)
|
|
|
|
Mixed Gas-gangrene Antitoxin
|
|
|
|
Leptospira Antiserum
|
|
|
|
Rabies Antiserum
|
|
|
|
Scorpion Venom Antiserum
|
|
|
|
Snake Venom Antiserum
|
|
|
|
Tetanus Antitoxin
|
|
|
|
Serum Gonadotrophin
|
|
|
|
Sermorelin
|
|
|
|
Sertindole
|
|
|
|
Sertraline Hydrochloride
|
|
|
|
Sevoflurane
|
|
|
|
Sibutramine Hydrochloride
|
|
|
|
Silver Sulphadiazine
|
|
|
|
Simvastatin
|
|
|
|
Sissomicin
|
|
|
|
Sissomicin Sulphate
|
|
|
|
Snake Venoms
|
|
|
|
Sodium Acetrizoate
|
|
|
|
Sodium Aminosalicylate
|
|
|
|
Sodium Antimonylgluconate
|
|
|
|
Sodium Arsanilate
|
|
|
|
Sodium Arsenate
|
|
|
|
Sodium Arsenite
|
0.013%
|
|
|
Sodium Bromide
|
|
|
|
Sodium Clodronate
|
|
|
|
Sodium Cromoglycate
|
|
Administration through the nose
|
|
Sodium Ethacrynate
|
|
|
|
Sodium Fluoride
|
(1) 0.33% (y)
|
(1) Dentifrices
|
|
|
|
(2) Other preparations for use in the prevention of dental of
dental caries in the form of –
(a)tablets or drops;
|
(a) 2.2 mg (MDD)
|
|
(b) 0.2%
|
(b) mouth-washes (other than those for daily use);
|
|
|
(c) 0.05%
|
(c) mouth-washes for daily use
|
|
Sodium Fusidate
|
|
|
|
Sodium Metrizoate
|
|
|
|
Sodium Monofluorophosphate
|
1.14% (y)
|
Dentifrice
|
|
Sodium Stibogluconate
|
|
|
|
Sodium Valproate
|
|
|
|
Somatorelin Acetate
|
|
|
|
Somatrem
|
|
|
|
Somatropin
|
|
|
|
Sotalol Hydrochloride
|
|
|
|
Sparfloxacin
|
|
|
|
Spectinomycin
|
|
|
|
Spectinomycin Hydrocloride
|
|
|
|
Spiramycin
|
|
|
|
Spiramycin Adipate
|
|
|
|
Spironolactone
|
|
|
|
Stannous Fluoride
|
(1) 0.62% (y)
|
(1) Dentifrice
|
|
|
(2) 0.4%
|
(2) Dental gels for use in the prevention and treatment of
dental caries and decalcification of the teeth
|
|
Stanolone
|
|
|
|
Stanozolol
|
|
|
|
Stavudine
|
|
|
|
Stilboestrol
|
|
|
|
Stilboestrol Dipropionate
|
|
|
|
Streptodornase
|
|
External
|
|
Streptokinase
|
|
External
|
|
Streptomycin
|
|
|
|
Streptomycin Sulphate
|
|
|
|
Strychnine
|
|
|
|
Strychnine Arsenate
|
|
|
|
Strychnine Hydrochloride
|
|
|
|
Strychnine Nitrate
|
|
|
|
Styramate
|
|
|
|
Succinylsulphathiazole
|
|
|
|
Sucralfate
|
|
|
|
Sulbactam
|
|
|
|
Sodium
|
|
|
|
Sulbenicillin
|
|
|
|
Sulbenicillin Sodium
|
|
|
|
Sulbenicillin Tosylate
|
|
|
|
Sulconazole Nitrate
|
|
External (except vaginal use)
|
|
Sulfacytine
|
|
|
|
Sulfadoxine
|
|
|
|
Sulfamonomethoxine
|
|
|
|
Sulindac
|
|
|
|
Sulphabenzamide
|
|
|
|
Sulphacetamide
|
|
|
|
Sulphacetamide Sodium
|
|
|
|
Sulphadiazine
|
|
|
|
Sulphadiazine Sodium
|
|
|
|
Sulphadimethoxine
|
|
|
|
Sulphadimidine
|
|
|
|
Sulphadimidine Sodium
|
|
|
|
Sulphafurazole
|
|
|
|
Sulphafurazole Diethanolamine
|
|
|
|
Sulphaguanidine
|
|
|
|
Sulphaloxic Acid
|
|
|
|
Sulphamerazine
|
|
|
|
Sulphamerazine Sodium
|
|
|
|
Sulphamethizole
|
|
|
|
Sulphamethoxazole
|
|
|
|
Sulphamethoxydazine
|
|
|
|
Sulphamethoxypyridazine
|
|
|
|
Sulphamethoxypyridazine Sodium
|
|
|
|
Sulphametopyrazine
|
|
|
|
Sulphamoxole
|
|
|
|
Sulphanilamide
|
|
|
|
Sulphaphenazole
|
|
|
|
Sulphapyridine
|
|
|
|
Sulphapyridine Sodium
|
|
|
|
Sulphasalazine
|
|
|
|
Sulphathiazole
|
|
|
|
Sulphathiazole Sodium
|
|
|
|
Sulphaurea
|
|
|
|
Sulphinpyrazone
|
|
|
|
Sulpiride
|
|
|
|
Sultamicillin
|
|
|
|
Sultamicillin Tosylate
|
|
|
|
Sulthiame
|
|
|
|
Sumatriptan
|
|
|
|
Sumatriptan Succinate
|
|
|
|
Suprofen
|
|
|
|
Suxamethonium Bromide
|
|
|
|
Suxamethonium Chloride
|
|
|
|
Suxethonium Bromide
|
|
|
|
Tacalcitol Monohydrate
|
|
|
|
Tacrine Hydrochloride
|
|
|
|
Talampicillin
|
|
|
|
Talampicillin Hydrochloride
|
|
|
|
Talampicillin Napsylate
|
|
|
|
Tamoxifen
|
|
|
|
Tamoxifen Citrate
|
|
|
|
Tamsulosin Hydrochloride
|
|
|
|
Tazarotene
|
|
|
|
Tazobactam Sodium
|
|
|
|
Teicoplanin
|
|
|
|
Temocapril Hydrochloride
|
|
|
|
Temocillin Sodium
|
|
|
|
Tenoxicam
|
|
|
|
Terazosan Hydrochloride
|
|
|
|
Terbinafine
|
|
|
|
Terbinafine Hydrochloride
|
|
|
|
Terbutaline
|
|
|
|
Terbutaline Sulphate
|
|
|
|
Terfenadine
|
|
|
|
Terodiline Hydrochloride
|
|
|
|
Tertipressin
|
|
|
|
Testosterone
|
|
|
|
Testosterone Acetate
|
|
|
|
Testosterone 17B Chloral Hemiacetal
|
|
|
|
Testosterone Cyclohexyl-propionate
|
|
|
|
Testosterone Cypionate
|
|
|
|
Testosterone Decanoate
|
|
|
|
Testosterone Enanthate
|
|
|
|
Testosterone Isocaproate
|
|
|
|
Testosterone Phenylpropionate
|
|
|
|
Testosterone Propionate
|
|
|
|
Testosterone Undecanoate
|
|
|
|
Tetrabenazine
|
|
|
|
Tetracosactrin
|
|
|
|
Tetracosactrin Acetate
|
|
|
|
Tetracycline
|
|
|
|
Tetracycline Hydrochloride
|
|
|
|
Tetracycline Phosphate Complex
|
|
|
|
Tetroxoprim
|
|
|
|
Thallium Acetate
|
|
|
|
Thallous Chloride
|
|
|
|
Thiabendazole
|
|
|
|
Thiambutosine
|
|
|
|
Thiethylperazine
|
|
|
|
Thiethylperazine Maleate
|
|
|
|
Thiocarlide
|
|
|
|
Thioguanine
|
|
|
|
Thiopentone Sodium
|
|
|
|
Thiopropazate Hydrochloride
|
|
|
|
Thioproperazine Mesylate
|
|
|
|
Thioridazine
|
|
|
|
Thioridazine Hydrochloride
|
|
|
|
Thiosinamine
|
|
|
|
Thiotepa
|
|
|
|
Thiothixene
|
|
|
|
Thiouracil
|
|
|
|
Thymoxamine Hydrochloride
|
|
|
|
Thyroid
|
|
|
|
Thyrotrophin
|
|
|
|
Thyroxine Sodium
|
|
|
|
Tiamulin Fumarate
|
|
|
|
Tiaprofenic Acid
|
|
|
|
Tibolone
|
|
|
|
Ticarcillin Sodium
|
|
|
|
Ticlopidine Hydrochloride
|
|
|
|
Tigloidine Hydrobromide
|
|
|
|
Tiludronate Disodium
|
|
|
|
Timolol Maleate
|
|
|
|
Tinidazole
|
|
|
|
Tinzaparin
|
|
|
|
Tioconazole
|
2.0%
|
(1) External, but in the case of vaginal use only, external use
for treatment of vaginal candidiasis
|
|
Tizanidine Hydrochloride
|
|
|
|
Tobramycin
|
|
|
|
Tobramycin Sulphate
|
|
|
|
Tocainide Hydrochloride
|
|
|
|
Tofenacin Hydrochloride
|
|
|
|
Tolazamide
|
|
|
|
Tolazoline Hydrochloride
|
|
External
|
|
Tolbutamide
|
|
|
|
Tolbutamide Sodium
|
|
|
|
Tolcapone
|
|
|
|
Tolfenamic Acid
|
|
|
|
Tolmetin Sodium
|
|
|
|
Topiramate
|
|
|
|
Torasemide
|
|
|
|
Toremifene
|
|
|
|
Tramadol Hydrochloride
|
|
|
|
Trandolapril
|
|
|
|
Tranexamic Acid
|
|
|
|
Tranylepromine Sulphate
|
|
|
|
Trazodone Hydrochloride
|
|
|
|
Treosulfan
|
|
|
|
Tretinoin
|
|
|
|
Triamcinolone
|
|
|
|
Triamcinolone Acetonide
|
|
|
|
Triamcinolone Diacetate
|
|
|
|
Triamcinolone Hexacetonide
|
|
|
|
Triamterene
|
|
|
|
Tribavirin
|
|
|
|
Triclofos Sodium
|
|
|
|
Trientine Dihydrochloride
|
|
|
|
Trifluoperazine
|
|
|
|
Trifluoperazine Hydrochloride
|
|
|
|
Trifluperidol
|
|
|
|
Trifluperidol Hydrochloride
|
|
|
|
Trilostane
|
|
|
|
Trimeprazine
|
|
|
|
Trimeprazine Tartrate
|
|
|
|
Trimetaphan Camsylate
|
|
|
|
Trimetazidine
|
|
|
|
Trimetazidine Hydrochloride
|
|
|
|
Trimethoprim
|
|
|
|
Trimipramine Maleate
|
|
|
|
Trimipramine Mesylate
|
|
|
|
Tropicamide
|
|
|
|
Tropisetron Hydrochloride
|
|
|
|
Troxidone
|
|
|
|
L-Tryptophan
|
|
(1) Dietary or nutritive use
(2) Any external use
|
|
Tubocurarine Chloride
|
|
|
|
Tulobuterol
|
|
|
|
Tulobuterol Hydrochloride
|
|
|
|
Tyrothricin
|
|
Throat lozenges or throat pastilles
|
|
Uramustine
|
|
|
|
Urea Stibamine
|
|
|
|
Urethane
|
|
|
|
Uridine-5-Triphosphoric Acid
|
|
|
|
Urofollitrophin
|
|
|
|
Urokinase
|
|
|
|
Ursodeoxychloric Acid
|
|
|
|
Vaccines –
|
|
|
|
Athrax
Vaccine
(Bacillus) Anthracis)
|
|
|
|
Bacillus Calmette-
Guerin
Vaccine
|
|
|
|
Bacillus Salmonella
Typhi
Vaccine
|
|
|
|
Percutaneous Bacillus
Calmette- Guerin
Vaccine
|
|
|
|
Cholera
Vaccine
|
|
|
|
Diphtheria Vaccine
|
|
|
|
Adsorbed Diphtheria
Vaccine
|
|
|
|
Diphtheria and Tetanus
Vaccine
|
|
|
|
Adsorbed Diphtheria
and
Tetanus Vaccine
|
|
|
|
Diphtheria, Tetanus
and
Pertussis Vaccine
|
|
|
|
Adsorbed Diphtheria,
Tetanus
and Pertussis
Vaccine
|
|
|
|
Diphtheria, Tetanus
and
Poliomyelitis
Vaccine
|
|
|
|
Diphtheria, Tetanus,
Pertussis and
Poliomyelitis Vaccine
|
|
|
|
Eltor
Vaccine
|
|
|
|
Influenza Vaccine
|
|
|
|
Hepatitis B Vaccine
|
|
|
|
Measles
Vaccine
(Live
Attenuated)
|
|
|
|
Meningococcal
Polysaccharide
Vaccine
|
|
|
|
Mumps
Vaccine
|
|
|
|
Pertussis Vaccine
|
|
|
|
Plague
Vaccine
|
|
|
|
Pneumococcal Vaccine
(Bacterial
Antigen)
|
|
|
|
Poliomyelitis Vaccine
(Inactivated)
|
|
|
|
Poliomyelitis Vaccine
(Live
Oral)
|
|
|
|
Rabies
Vaccine
|
|
|
|
Rubella
Vaccine (Live
Attenuated)
|
|
|
|
Rubella, Mumps,
Measles
Vaccine
|
|
|
|
Tetanus
Vaccine
|
|
|
|
Adsorbed Tetanus
Vaccine
|
|
|
|
Tetanus
and Pertussis
Vaccine
|
|
|
|
Tuberculin Purified
Protein
Derivative
|
|
|
|
Old
Tuberculin
|
|
|
|
Typhoid
Vaccine
|
|
|
|
Typhoid
– Paratyphoid
A and B
Vaccine
|
|
|
|
Typhoid
– Paratyphoid
A and B
and Cholera
Vaccine
|
|
|
|
Typhoid
– Paratyphoid
A and B
and Tetanus
Vaccine
|
|
|
|
Typhus
Vaccine
|
|
|
|
Yellow
Fever Vaccine
|
|
|
|
Valaciclovir
|
|
|
|
Valaciclovir Hydrochloride
|
|
|
|
Valproic Acid
|
|
|
|
Valsartan
|
|
|
|
Vancomycin Hydrochloride
|
|
|
|
Vasopressin Injection
|
|
|
|
Vasopressin Tannate
|
|
|
|
Vecuronium Bromide
|
|
|
|
Venlafaxine
|
|
|
|
Venlafaxine Hydrochloride
|
|
|
|
Verapamil Hydrochloride
|
|
|
|
Veratrine
|
|
|
|
Veratrum
(Green and White)
|
|
|
|
Vidarabine
|
|
|
|
Vigabatrin
|
|
|
|
Viloxazine Hydrochloride
|
|
|
|
Vinblastine Sulphate
|
|
|
|
Vincristine Sulphate
|
|
|
|
Vindesine Sulphate
|
|
|
|
Viomycin Pantothenate
|
|
|
|
Viomycin Sulphate
|
|
|
|
Vitamin A
|
|
(1) Internal
|
(1) 7500 iu (2250 mcg Retinol equivalent) (MDD)
|
|
|
(2) External
|
|
Vitamin A Acetate
|
|
(1) Internal
|
(1) Equi-valent to 7500 iu Vitamin A (2250 mcg Retinol
equivalent) (MDD)
|
|
|
(2) External
|
|
Vitamin A Palmitate
|
|
(1) Internal
|
(1) Equi-valent to 7500 iu Vitamin A (2250 mcg Retinol
equivalent) (MDD)
|
|
|
(2) External
|
|
Warfarin
|
|
|
|
Warfarin Sodium
|
|
|
|
Xamoterol Fumarate
|
|
|
|
Xipamide
|
|
|
|
Yohimbine Hydrochloride
|
|
|
|
Zalcitabine
|
|
|
|
Zidovudine
|
|
|
|
Zimeldine Hydrochloride
|
|
|
|
Zolmitriptan
|
|
|
|
Zolpidem
|
|
|
|
Zomepirac Sodium
|
|
|
|
Zopiclone
|
|
|
|
Zuclopenthixol Acetate
|
|
|
|
Zuclopenthixol Decanoate
|
|
|
|
Zuclopenthixol Hydrochloride
|
|
|
|
Note –
|
1. In relation to a medicinal product that contains more than
one of the substances Atropine, Atropine Methobromide, Atropine Methonitrate,
Atropine Oxide Hydrochloride, Atropine Sulphate, Hyoscine, Hyoscine
Butylbromide, Hyoscine Hydrobromide, Hyoscine Methobromide, Hyoscine
Methonitrate, Hyoscyamine, Hyoscyamine Hydrobromide and Hyoscyamine Sulphate,
the maximum daily dose for the purposes of column 4 is 1 mg of the total
alkaloids contained in the product that are derived from Belladonna,
Hyoscyamus, Stramonium or other solanaceous plant, and there is no maximum
dose.
|
|
2. In relation to a
medicinal product that contains more than one of the substances Sodium
Fluoride, Sodium Monofluorophosphate and Stannous Fluoride combined in a
dentifrice, the maximum strength of the combination for the purposes of
column 2 shall not exceed 0.15% calculated as Fluorine.
|
PART 2
(Articles 1(2),
3(2) and 7)
Controlled Drugs
|
Circumstances In Which
Controlled Drugs Are Not Prescription Only Medicines
|
Column 1
|
Column 2
|
Column 3
|
Column 4
|
Substance
|
Maximum strength
|
Pharmaceutical form
|
Maximum dose
|
Codeine; its salts
|
Equivalent of 1.5% of Codeine Monohydrate
|
|
Equivalent of 20 mg of Codeine Monohydrate
|
Dihydrocodeine; its salts
|
Equivalent of 1.5%of Dihydrocodeine
|
|
Equivalent of 10 mg of Dihydroco-deine
|
Ethylmorphine; its salts
|
Equivalent of 0.2% of Ethylmorphine
|
|
Equivalent of 7.5 mg of Ethyl-morphine
|
Morphine; its salts
|
(1) Equivalent of 0.02% of anhydrous Morphine
|
(1) Liquid
|
(1) Equivalent of 3 mg of anhydrous Morphine
|
|
(2) Equivalent of 0.04% of anhydrous Morphine; equivalent of 300
mcg of anhydrous Morphine
|
(2) Solid
|
(2) Equivalent of 3 mg of anhydrous Morphine
|
Medicinal Opium
|
(1) Equivalent of 0.02%of anhydrous Morphine
|
(1) Liquid
|
(1) Equivalent of 3 mg of anhydrous Morphine
|
|
(2) Equivalent of 0.04% of anhydrous Morphine
|
(2) Solid
|
(2) Equivalent of 3 mg of anhydrous Morphine
|
Pholcodine; its salts
|
Equivalent of 1.5% of Pholcodine
|
|
Equivalent of 20 mg of Pholcodine
|
PART 3
(Article 3(4))
NAMED PRODUCTS THAT ARE NOT
PRESCRIPTION ONLY MEDICINES
TABLE A
|
Name and product licence number of
medicinal products that are not prescription only medicines
|
Adcortyl in Orabase for Mouth Ulcers
|
0034/0321
|
Anusol Plus HC Ointment
|
0018/0223
|
Anusol Plus HC Suppositories
|
0018/0224
|
Beechams Hydrocortisone Cream
|
0079/0203
|
Boots Hydrocortisone Ointment
|
0014/0364
|
Calacort Cream
|
12650/0001
|
Canesten Hydrocortisone Cream
|
0010/0216
|
Corlan Pellets
|
0039/0397
|
Cortaid Cream 1%
|
0032/0126
|
Corteze Cream
|
0001/0107
|
Cortiderm
|
2855/0010
|
Cortril Topical Ointment 1% (non-greasy)
|
0057/0251
|
Dermacort Hydrocortisone Cream
|
8265/0002
|
Dioderm Hydrocortisone Cream
|
0173/0153
|
Efcortelan Eczema Cream
|
10949/0234
|
Efcortelan Eczema Ointment
|
10949/0235
|
Eurax HC Cream
|
0001/5010R
|
Hc45 Hydrocortisone Cream
|
0327/0039
|
Herpetad Cold Sore Cream
|
4986/0007
|
Jungle Formula Bite & Sting Relief Cream
|
2855/0010
|
Lanacort Cream
|
3157/0008
|
Lanacort Ointment
|
3157/0011
|
Perinal Spray
|
0173/0049
|
Pharmacort Cream 0.5%
|
0011/0077
|
Proctocream HC
|
0036/0065
|
Soothelip Cold Sore Cream
|
0142/0426
|
Timocort Hydrocortisone Cream
|
0044/0090
|
Timocort Hydrocortisone Cream 1%
|
0063/0076
|
Wasp-Eze Hydrocortisone Cream
|
8452/0012
|
Zaclovir Cold Sore Cream
|
4986/0007
|
Zenoxone Cream
|
0181/0033
|
Zovirax Cold Sore Cream
|
0003/0304
|
PART
4[12]
(Article 3(4))
OTHER MEDICINAL PRODUCTS
THAT ARE NOT PRESCRIPTION ONLY MEDICINES
1 A
medicinal product shall not be a prescription only medicine by reason that it
contains the substance aciclovir, where –
(a) the maximum strength of the aciclovir in the
medicinal product does not exceed 5%;
(b) the medicinal product is sold or supplied in
a container, or package, containing not more than 2 g of the medicinal product;
and
(c) the medicinal product is indicated only for
external application for the treatment of herpes simplex virus infections of
the lips and face (Herpes labialis).
2 A
medicinal product shall not be a prescription only medicine by reason that it
contains the substance acrivastine, where –
(a) the medicinal product is sold or supplied in
a container, or package, containing not more than 240 mg of acrivastine; and
(b) the container or package is labelled to show
a maximum daily dose of 24 mg of acrivastine.
3 A
medicinal product shall not be a prescription only medicine by reason that it
contains the substance aloxiprin, where –
(a) the medicinal product is in the form of
non-effervescent tablets or capsules;
(b) the maximum strength of the medicinal
product in each tablet or capsule does not exceed 620 mg;
(c) the quantity (of tablets or capsules, or of
any combination of tablets and capsules) that is sold or supplied in one
container or package does not exceed 32; and
(d) the quantity (of tablets or capsules, or of
any combination of tablets and capsules) that is sold or supplied to a person
at any one time does not exceed 100.
4 A
medicinal product shall not be a prescription only medicine by reason that it
contains the substance aloxiprin, where it is not in the form of a
non-effervescent tablet or capsule.
5 A
medicinal product shall not be a prescription only medicine by reason that it
contains the substance aspirin, where –
(a) the medicinal product is in the form of
non-effervescent tablets or capsules;
(b) the maximum strength of the medicinal
product in each tablet or capsule does not exceed 75 mg;
(c) the quantity (of tablets or capsules, or of
any combination of tablets and capsules) that is sold or supplied in one
container or package does not exceed 100; and
(d) the quantity (of tablets or capsules, or of
any combination of tablets and capsules) that is sold or supplied to a person
at any one time does not exceed 100.
6 A
medicinal product shall not be a prescription only medicine by reason that it
contains the substance aspirin, where –
(a) the medicinal product is in the form of
non-effervescent tablets or capsules;
(b) the maximum strength of the medicinal
product in each tablet or capsule does not exceed 325 mg;
(c) the quantity (of tablets or capsules, or of
any combination of tablets and capsules) that is sold or supplied in one
container or package does not exceed 32; and
(d) the quantity (of tablets or capsules, or of
any combination of tablets and capsules) that is sold or supplied to a person
at any one time does not exceed 100.
7 A
medicinal product shall not be a prescription only medicine by reason that it
contains the substance azelastine hydrochloride, where –
(a) the medicinal product is in non-aerosol,
aqueous form for nasal administration;
(b) the medicinal product is sold or supplied in
a container, or package, containing not more than 36 doses each of which
contains not more than 140 mcg of azelastine hydrochloride;
(c) the container or package is labelled to show
a maximum dose of 140 mcg per nostril and a maximum daily dose of 280 mcg per
nostril of azelastine hydrochloride; and
(d) the medicinal product is indicated only for
the treatment of seasonal allergic rhinitis or perennial allergic rhinitis, in
persons aged not less than 5 years.
8 A
medicinal product shall not be a prescription only medicine by reason that it
contains the substance azelastine hydrochloride, where –
(a) the medicinal product is in the form of eye
drops; and
(b) it is indicated only for the treatment of
allergic conjunctivitis, in persons aged not less than 12 years.
9 A medicinal product shall not be a prescription only medicine by
reason that it contains the substance beclomethasone dipropionate,
where –
(a) the medicinal product is in non-aerosol form
for nasal administration;
(b) the medicinal product is sold or supplied in
a container, or package, containing not more than 5,600mcg of beclomethasone
diopropionate;
(c) the container or package is labelled to show
a maximum dose of 100 mcg per nostril and a maximum daily dose of 200 mcg
per nostril of beclomethasone dipropionate; and
(d) the medicinal product is indicated only for
the prevention of treatment of allergic rhinitis, in persons aged not less than
12 years.
10 A
medicinal product shall not be a prescription only medicine by reason that it
contains the substance budesonide, where –
(a) the medicinal product is in non-aerosol,
aqueous form for nasal administration;
(b) the medicinal product is sold or supplied in
a container, or package, containing not more than 10 mg of the medicinal
product;
(c) the container or package is labelled to show
a maximum dose, and a maximum daily dose, of 200 mcg per nostril of
budesonide; and
(d) the medicinal product is indicated only for
the prevention of treatment of seasonal allergic rhinitis, in persons aged not
less than 12 years.
11 A
medicinal product shall not be a prescription only medicine by reason that it
contains the substance carbenoxolone sodium, where –
(a) the medicinal product is in the form of
granules;
(b) the maximum strength of the carbenoxolone
sodium in the medicinal product does not exceed 1%, calculated in terms of
weight in weight;
(c) the medicinal product is sold or supplied in
a container, or package, containing not more than 560 mg of carbenoxolone
sodium;
(d) the container or package is labelled to show
a maximum dose of 20 mg and a maximum daily dose of 80 mg of carbenoxolone
sodium; and
(e) the medicinal product is indicated only for
treatment by mouthwash, in persons aged not less than 12 years.
12 A
medicinal product shall not be a prescription only medicine by reason that it
contains the substance cetirizine, where –
(a) the medicinal product is sold or supplied in
a container, or package, containing not more than 100 mg of cetirizine; and
(b) the container or package is labelled to show
a maximum daily dose of 10mg of cetirizine.
13 A
medicinal product shall not be a prescription only medicine by reason that it
contains the substance cimetidine, where –
(a) the container or package in which the
medicinal product is sold or supplied is labelled to show a maximum dose
of 200 mg and a maximum daily dose of 800 mg of cimetidine for a maximum
period of 14 days; and
(b) the medicinal product is indicated for the
short-term symptomatic relief of heartburn, dyspepsia and hyperacidity and for
the prophylaxsis of meal-induced heartburn.
14 A
medicinal product shall not be a prescription only medicine by reason that it
contains the substance cimetidene, where –
(a) the medicinal product is for the
prophylactic management of nocturnal heartburn; and
(b) the container or package in which the
medicinal product is sold or supplied is labelled to show a maximum dose of 100
mg of cimetidine to be taken once daily at night for a maximum period of 14
days.
15 A
medicinal product shall not be a prescription only medicine by reason that it
contains the substance clobetasone butyrate, where –
(a) the medicinal product is in the form of a
cream;
(b) the maximum strength of the clobetasone
butyrate in the medicinal product does not exceed 0.05%;
(c) the medicinal product is sold or supplied in
a container, or package, containing not more than 15 g of the medicinal
product; and
(d) the medicinal product is indicated only for
external application for the short-term treatment of eczema and dermatitis, in
persons aged not less than 12 years.
16 A
medicinal product shall not be a prescription only medicine by reason that it
contains the substance diclofenac diethylammonium, where –
(a) the maximum strength of the diclofenac
diethylammonium in the medicinal product does not exceed 1.16%, calculated in
terms of weight in weight;
(b) the medicinal product is sold or supplied in
a container, or package, containing not more than 30 g of the medicinal
product;
(c) the container or package is labelled to show
a maximum period of use of 7 days; and
(d) the medicinal product is indicated for
external application for the local symptomatic relief of pain and inflammation
in trauma of the tendons, ligaments, muscles and joints and in localized forms
of soft tissue rheumatism, in persons aged not less than 12 years.
17 A
medicinal product shall not be a prescription only medicine by reason that it
contains the substance domperidone, where –
(a) the medicinal product is indicated for the
relief of post-prandial symptoms of excessive fullness, nausea, epigastric
bloating and belching, occasionally accompanied by epigastric discomfort and
heartburn;
(b) the medicinal product is sold or supplied in
a container or package containing not more than 200 mg of domperidone; and
(c) the container or package is labelled to show
a maximum dose of 10 mg of domperidone and a maximum daily dose of 40 mg
of domperidone.
18 A
medicinal product shall not be a prescription only medicine by reason that it
contains the substance domperidone maleate, where –
(a) the medicinal product is sold in a
container, or package, containing not more than 200 mg of domperidone
maleate;
(b) the container or package is labelled to show
a maximum dose of 10 mg and a maximum daily dose of 40 mg; and
(c) the medicinal product is indicated for use
for the relief of postprandial symptoms of excessive fullness, nausea,
epigastric bloating and belching, accompanied by epigastric discomfort and
heartburn.
19 A
medicinal product shall not be a prescription only medicine by reason that it
contains the substance famotidine, where –
(a) the container or package in which the
medicinal product is sold or supplied is labelled to show a maximum dose of 10
mg and a maximum daily dose of 20 mg of famotidine for a maximum period of
14 days; and
(b) the medicinal product is indicated
for –
(i) the short-term
symptomatic relief of heartburn, dyspepsia, indigestion, acid indigestion or
hyperacidity, or
(ii) the
prevention of the symptoms of heartburn, dyspepsia, indigestion, acid indigestion
or hyperacidity where they are associated with the consumption of food or
drink, including the prevention of sleep disturbance because of those symptoms.
20 A
medicinal product shall not be a prescription only medicine by reason that it
contains the substance felbinac, where –
(a) the maximum strength of the felbinac in the
medicinal product does not exceed 3.17%, calculated in terms of weight in
weight;
(b) the medicinal product is sold or supplied in
a container, or package, containing not more than 50 g of the medicinal
product;
(c) the container or package is labelled to show
a maximum period of use of 7 days; and
(d) the medicinal product is indicated for
external application for the relief of symptoms associated with soft tissue
injury such as strains, sprains and contusions, in persons aged not less than
12 years.
21 A
medicinal product shall not be a prescription only medicine by reason that it
contains the substance fluconazole, where –
(a) the medicinal product is sold or supplied in
a container, or package, containing not more than 150 mg of the medicinal
product;
(b) the container or package is labelled to show
a maximum dose of 150 mg of fluconazole; and
(c) the medicinal product is indicated for oral
administration for the treatment of vaginal candidiasis or associated candidal
balanitis, in persons aged not less than 16 years but less than 60 years.
22 A
medicinal product shall not be a prescription only medicine by reason that it
contains the substance flunisolide, where –
(a) the medicinal product is in the form of a
non-pressurized nasal spray;
(b) the maximum strength of the flunisolide in
the medicinal product does not exceed 0.025%, calculated in terms of weight in
volume;
(c) the medicinal product is sold or supplied in
a container, or package, containing not more than 240 metered doses of the
medicinal product;
(d) the container or package is labelled to show
a maximum dose of 50 mcg per nostril and a maximum daily dose of 100 mcg per
nostril of flunisolide in the case of persons aged not less than 16 years,
and a maximum dose of 25 mcg per nostril and a maximum daily dose of 75 mcg per
nostril in the case of children aged not less than 12 years but less
than 16 years; and
(e) the medicinal product is indicated for the
prevention and treatment of seasonal allergenic rhinitus, including hay fever,
in persons aged not less than 12 years.
23 A
medicinal product shall not be a prescription only medicine by reason that it
contains the substance hydrocortisone, where –
(a) the maximum strength of the hydrocortisone
in the medicinal product does not exceed 0.5%, calculated in terms of weight in
weight;
(b) the medicinal product is sold or supplied in
a container, or package, containing not more than 15 g of the medicinal
product; and
(c) the medicinal product is indicated for
external use in combination with nystatin of a maximum strength of 3.0%, for
intertrigo, in persons aged not less than 10 years.
24 A
medicinal product shall not be a prescription only medicine by reason that it
contains the substance hydrocortisone, where –
(a) the medicinal product is in the form of a
cream, ointment or spray;
(b) the maximum strength of the hydrocortisone
in the medicinal product does not exceed 1.0%, calculated in terms of weight in
weight;
(c) the medicinal product is sold or supplied in
a container, or package, containing –
(i) where the
medicinal product is in the form of a cream or ointment, not more than 15 g of
the medicinal product, or
(ii) where
the medicinal product is in the form of a spray, not more than 30 ml of the
medicinal product;
(d) the medicinal product is indicated for
external use, either alone or in conjunction with crotamiton in irritant
dermatitis, contact allergic dermatitis, insect bite reactions or mild to
moderate eczema, and either in combination with clotrimazole or miconazole
nitrate for athlete’s foot and candidal intertrigo or in combination with
lignocaine for anal and perianal itch associated with haemorrhoids; and
(e) the medicinal product is indicated for use
in persons aged not less than 10 years.
25 A
medicinal product shall not be a prescription only medicine by reason that it
contains the substance hydrocortisone acetate, where –
(a) the medicinal product is in the form of a
cream or ointment, or suppositories;
(b) the maximum strength of the hydrocortisone
acetate in the medicinal product is equivalent to 1.0% of hydrocortisone,
calculated in terms of weight in weight;
(c) the medicinal product is sold or supplied in
a container, or package, containing –
(i) where the
medicinal product is in the form of a cream or ointment, not more than 15 g of
the medicinal product, or
(ii) where
the medicinal product is in the form of suppositories, not more than 12
suppositories;
(d) the medicinal product is indicated for
external use -
(i) for irritant
dermatitis, contact allergic dermatitis, insect bite reactions or mild to
moderate eczema,
(ii) in
combination with one or more of the following, namely benzyl benzoate, bismuth
oxide, bismuth subgallate, peru balsam, pramoxine hydrochloride and zinc oxide,
for haemorrhoids, or
(iii) in
combination with miconazole nitrate, for tinea pedis or candidal intertrigo;
and
(e) the medicinal product is indicated for use
in persons aged not less than 10 years.
26 A
medicinal product shall not be a prescription only medicine by reason that it
contains the substance hydrocortisone sodium succinate, where –
(a) the medicinal product is in the form of
pellets;
(b) the maximum strength of the hydrocortisone
sodium succinate in the medicinal product is equivalent to 2.5 mg of
hydrocortisone, calculated in terms of weight in weight;
(c) the medicinal product is sold or supplied in
a container, or package, containing the equivalent of 50 mg of hydrocortisone;
and
(d) the medicinal product is indicated for
external use for aphthous ulceration of the mouth, in persons aged not less
than 12 years.
27 A
medicinal product shall not be a prescription only medicine by reason that it
contains the substance hydroxyzine hydrochloride, where –
(a) the medicinal product is sold or supplied in
a container, or package, containing not more than 750 mg of the medicinal
product;
(b) the container or package is labelled to show
a maximum dose of 25 mg, and to show a maximum daily dose of 75 mg in the case
of persons aged not less than 12 years and a maximum daily dose of 50 mg in the
case of children aged not less than 6 years but less than 12 years; and
(c) the medicinal product is indicated for the
management of pruritus associated with acute or chronic urticaria or atopic
dermatitis or contact dermatitis, in persons aged not less than 6 years.
28 A
medicinal product shall not be a prescription only medicine by reason that it
contains the substance hyoscine butylbromide, where –
(a) the route of administration of the medicinal
product is internal and is otherwise than by means of an inhaler;
(b) the medicinal product is sold or supplied in
a container, or package, containing not more than 240 mg of the medicinal
product; and
(c) the container or package is labelled to show
a maximum dose of 20 mg and a maximum daily dose of 80 mg of the medicinal
product.
29 A
medicinal product shall not be a prescription only medicine by reason that it
contains the substance Ibuprofen, where –
(a) the medicinal product is indicated for the
relief of rheumatic and muscular pain, pain of non-serious arthritic
conditions, backache, neuralgia, migraine, headache, dental pain,
dysmenorrhoea, feverishness, symptoms of colds and influenza; and either
(b) the route of the administration of the
medicinal product is internal; and –
(i) in the case of a
prolonged release preparation the container or package is labelled to show a
maximum dose of 600 mg and a maximum daily dose of 1200 mg, or
(ii) in
any other case the container or package is labelled to show a maximum dose of
400 mg and a maximum daily dose of 1200 mg; or
(c) the route of administration of the medicinal
product is external; and
(i) the maximum
strength of the Ibuprofen in the medicinal product does not exceed 5%, or
(ii)
(A) the maximum
strength of the Ibuprofen in the medicinal product does not exceed 10%, and
(B) the
medicinal product is sold or supplied in a container or package containing not
more than 50 g of medicinal product which is labelled to show a maximum dose of
125 mg and a maximum daily dose of 500 mg.
30 A
medicinal product shall not be a prescription only medicine by reason that it
contains the substance ketoconazole, where –
(a) the medicinal product is in the form of a
shampoo;
(b) the maximum strength of the ketoconazole in
the medicinal product does not exceed 2%, calculated in terms of weight in
weight;
(c) the medicinal product is sold or supplied in
a container, or package, containing not more than 120 ml of the medicinal
product and containing in the medicinal product not more than 2,400 mg of
ketoconazole;
(d) the container or package is labelled to show
a maximum frequency of application of once every 3 days; and
(e) the medicinal product is indicated for the
prevention and treatment of dandruff and seborrhoeic dermatitis of the scalp.
31 A
medicinal product shall not be a prescription only medicine by reason that it
contains the substance ketoprofen, where –
(a) the maximum strength of the ketoprofen in
the medicinal product does not exceed 2.5%, calculated in terms of weight in
weight;
(b) the medicinal product is sold or supplied in
a container, or package, containing not more than 30 g of the medicinal
product; and
(c) the medicinal product is indicated only for
treatment by external topical application, for rheumatic and muscular pain, in
persons aged not less than 12 years, for a maximum period of 7 days.
32 A
medicinal product shall not be a prescription only medicine by reason that it
contains the substance levocabastine hydrochloride, where –
(a) the medicinal product is in the form of a
nasal spray;
(b) the maximum strength of the medicinal
product does not exceed the equivalent of 0.05% levocabastine;
(c) the medicinal product is sold or supplied in
a container, or package, containing not more than 10 ml of the medicinal
product; and
(d) the medicinal product is indicated for the
symptomatic treatment of seasonal allergic rhinitis.
33 A
medicinal product shall not be a prescription only medicine by reason that it
contains the substance levocabastine hydrochloride, where –
(a) the medicinal product is in the form of
aqueous eye drops;
(b) the maximum strength of the medicinal
product does not exceed the equivalent of 0.05% levocabastine;
(c) the medicinal product is sold or supplied in
a container, or package, containing not more than 4ml of the medicinal product;
and
(d) the medicinal product is indicated for the
symptomatic treatment of seasonal allergic conjunctivitis.
34 A
medicinal product shall not be a prescription only medicine by reason that it
contains the substance loratadine, where –
(a) the medicinal product is sold or supplied in
a container, or package, containing not more than 100 mg of loratadine; and
(b) the container or package is labelled to show
a maximum daily dose of 10 mg of loratadine.
35 A
medicinal product shall not be a prescription only medicine by reason that it
contains the substance mebendazole, where –
(a) the medicinal product is sold or supplied in
a container, or package, containing not more than 800 mg of mebendazole;
(b) the container or package is labelled to show
a maximum dose of 100 mg of mebendazole; and
(c) the medicinal product is indicated for oral
use in the treatment of enterobiasis, in persons aged not less than 2 years.
36 A
medicinal product shall not be a prescription only medicine by reason that it
contains the substance nedocromil sodium, where –
(a) the maximum strength of the nedocromil
sodium in the medicinal product does not exceed 2.0%, calculated in terms of
weight in volume;
(b) the medicinal product is sold in a
container, or package, containing not more than 3 ml of the medicinal product;
and
(c) the medicinal product is indicated for the
prevention, relief and treatment of seasonal and perennial allergic
conjunctivitis.
37 A
medicinal product shall not be a prescription only medicine by reason that it
contains the substance nizatidine, where –
(a) the container or package in which the
medicinal product is sold or supplied is labelled to show a maximum dose of 75
mg of nizatidine and a maximum of 4 such doses in any period of 14 days; and
(b) the medicinal product is indicated only for
the prevention of the symptoms of food-related heartburn, in persons aged not
less than 16 years.
38 A
medicinal product shall not be a prescription only medicine by reason that it
contains the substance nystatin, where –
(a) the maximum strength of the nystatin in the
medicinal product does not exceed 3.0%, calculated in terms of weight in
weight;
(b) the medicinal product is sold in a
container, or package, containing not more than 15 g of the medicinal product;
and
(c) the medicinal product is indicated for
external use in combination with hydrocortisone of a maximum strength of 0.5%
for intertrigo, in persons aged not less than 10 years.
39 A
medicinal product shall not be a prescription only medicine by reason that it
contains the substance oxethazaine, where –
(a) the medicinal product is sold or supplied in
a container, or package, containing not more than 400 ml of oxethazaine; and
(b) the container or package is labelled to show
a maximum dose of 10 ml and a maximum daily dose of 30 ml of oxethazaine.
40 A
medicinal product shall not be a prescription only medicine by reason that it
contains the substance paracetamol, where –
(a) the medicinal product is in the form of
non-effervescent tablets or capsules;
(b) the maximum strength of the medicinal
product in each tablet or capsule does not exceed 500 mg;
(c) the quantity (of tablets or capsules, or of
any combination of tablets and capsules) that is sold or supplied in one
container or package does not exceed 32;
(d) the quantity (of tablets or capsules, or of
any combination of tablets and capsules) that is sold or supplied to a person
at any one time does not exceed 100; and
(e) the medicinal product is indicated for use
by administration wholly or mainly
to persons aged not less than 12 years.
41 A
medicinal product shall not be a prescription only medicine by reason that it
contains the substance paracetamol, where –
(a) the medicinal product is in the form of
non-effervescent tablets or capsules;
(b) the maximum strength of the medicinal
product in each tablet or capsule does not exceed 250 mg;
(c) the quantity (of tablets or capsules, or of
any combination of tablets and capsules) that is sold or supplied in one
container or package does not exceed 32; and
(d) the quantity (of tablets and capsules, or of
any combination of tablets and capsules) that is sold or supplied to a person
at any one time does not exceed 100.
42 A
medicinal product shall not be a prescription only medicine by reason that it
contains the substance piroxicam, where –
(a) the maximum strength of the piroxicam in the
medicinal product does not exceed 0.5%;
(b) the medicinal product is sold or supplied in
a container, or package, containing not more than 30 mg of the medicinal
product;
(c) the container or package is labelled to show
a maximum period of use of 7 days; and
(d) the medicinal product is indicated for
external application for the relief of rheumatic pain, pain of non-serious
arthritic conditions and muscular aches, pains and swellings such as strains,
sprains and sports injuries, in persons aged not less than 12 years.
43 A medicinal product shall not be a prescription only medicine by
reason that it contains the substance prochlorperazine maleate, where –
(a) the
medicinal product is in the form of tablets;
(b) the
maximum amount of the prochlorperazine maleate in the medicinal product, in
each tablet, does not exceed 3 mg;
(c) the medicinal product is sold or supplied in
a container, or package, containing not more than 8 tablets; and
(d) the medicinal product is indicated only for
nausea, and vomiting, in previously diagnosed migraine, in persons aged not
less than 18 years.
44 A
medicinal product shall not be a prescription only medicine by reason that it
contains the substance pyrantel embonate, where –
(a) the medicinal product is sold or supplied in
a container, or package, containing not more than 750 mg of the medicinal
product;
(b) the container or package is labelled to show
a maximum daily dose (to be taken as a single dose) of pyrantel embonate of 750
mg in the case of persons aged not less than 12 years, of 500 mg in the case of
children aged not less than 6 years but less than 12 years, and of 250 mg in
the case of children aged not less than 2 years but less than 6 years; and
(c) the medicinal product is indicated for the
treatment of enterobiasis, in persons aged not less than 2 years.
45 A
medicinal product shall not be a prescription only medicine by reason that it
contains the substance ranitidine hydrochloride, where –
(a) the container or package in which the
medicinal product is sold or supplied is labelled to show a maximum dose
equivalent to 75 ml and a maximum daily dose equivalent to 300 ml of ranitidine
for a maximum period of use of 14 days; and
(b) the medicinal product is indicated for the
short-term symptomatic relief of heartburn, dyspepsia and hyperacidity, or the
prevention of those symptoms when associated with the consumption of food and
drink.
46 A
medicinal product shall not be a prescription only medicine by reason that it
contains the substance sodium cromoglycate, where –
(a) the medicinal product is in the form of
aqueous eye drops;
(b) the maximum strength of the sodium
cromoglycate in the medicinal product does not exceed 2%, calculated in terms
of weight in volume;
(c) the medicinal product is sold or supplied in
a container containing not more than 10 ml of the medicinal product; and
(d) the medicinal product is indicated for
treatment of acute seasonal allergic conjunctivitis.
47 A
medicinal product shall not be a prescription only medicine by reason that it
contains the substance sodium cromoglycgate, where –
(a) the medicinal product is in the form of an
eye ointment;
(b) the maximum strength of the sodium
cromoglycate in the medicinal product is 4%, calculated in terms of weight in
weight;
(c) the medicinal product is sold or supplied in
a container, or package, containing not more than 5 g of the medicinal product;
and
(d) the medicinal product is indicated for the
treatment of acute seasonal allergic conjunctivitis or perennial allergic
conjunctivitis.
48 A medicinal product shall not be a prescription only medicine by
reason of the fact that it contains terbinafine, where –
(a) the maximum strength of the terbinafine in
the medicinal product does not exceed 1%;
(b) the medicinal product is sold or supplied in
a container, or package, containing not more than 30 g of the medicinal product;
and
(c) the medicinal product is indicated for
external use as a gel for the treatment of tina corporis, tinea pedis and tinea
cruris.
49 A
medicinal product shall not be a prescription only medicine by reason of the
fact that it contains terbinafine hydrochloride where –
(a) the maximum strength of the terbinafine
hydrochloride in the medicinal product does not exceed 1%;
(b) the medicinal product is indicated for
external use for the treatment of tinea pedis and tinea cruris; and
(c) the medicinal product is sold or supplied in
a container or package containing not more than 15 g of medicinal product.
50 A
medicinal product shall not be a prescription only medicine by reason of the
fact that it contains terbinafine hydrochloride, where –
(a) the maximum strength of the terbinafine
hydrochloride in the medicinal product does not exceed 1%;
(b) the medicinal product is sold or supplied in
a container containing not more than 30 ml of the medicinal product; and
(c) the medicinal product is indicated for
external use as a spray solution for the treatment of tina corporis, tinea
pedis and tinea cruris.
51 A
medicinal product shall not be a prescription only medicine by reason of the
fact that it contains triamcinolone acetonide where –
(a) the medicinal product is in the form of a
non-pressurised nasal spray;
(b) the medicinal product is indicated for the
treatment of symptoms of seasonal allergic rhinitis in persons aged 18
years and over for a maximum period of 3 months;
(c) the container or package is labelled to show
a maximum dose of 110 mcg per nostril and a maximum daily dose of 110 mcg per
nostril; and
(d) the medicinal product is sold or supplied in
a container or package containing not more than 3.375 mg of triamcinolone
acetonide.
SCHEDULE 2
EXEMPTION FOR CERTAIN
PERSONS FROM ARTICLE 57(2) OF THE LAW
PART 1[13]
(Articles 1(2)(a)
and 8(1))
Column 1
|
Column 2
|
Column 3
|
Persons exempted
|
Prescription only medicines to
which the exemption applies
|
Conditions
|
1. Persons selling or supplying prescription only medicines to
universities, other institutions concerned with higher education or
institutions concerned with research.
|
1. All prescription only medicines.
|
1.(1) The sale or supply shall be subject to the presentation of
an order, signed by the principal of the institution or the appropriate head
of department in charge of a specified course of research.
|
|
|
(2) The order shall specify–
|
(a) the name of the institution for which the prescription only
medicine is required;
|
(b) the purpose for which the prescription only medicine is
required; and
|
(c) the total quantity required.
|
(3) The sale or supply shall be only for the purposes of the
education or research with which the institution is concerned.
|
2. Persons selling or supplying prescription only medicines to
any of the following persons –
(a) the Official Analyst appointed under the Official
Analyst (Jersey) Law 2022, or any person appointed under that Law
to deputise for the Official Analyst;
|
2. All prescription only medicines.
|
2.(1) The sale or supply shall be subject to the presentation of
an order signed by or on behalf of any person listed in any of paragraph
2(a), (b) and (c) of column 1 of this Part of this Schedule.
(2) The order shall specify the status of the person signing it,
and the amount of the prescription only medicine required.
|
(b) an authorized officer within the meaning of the Food Safety
(Jersey) Law 1966; and
|
|
(3) The sale or supply shall be only in connection with the
exercise by the person of his or her statutory functions.
|
(c) a person duly authorized by the Minister under
Article 96 or 97 of the Law.
|
|
3. Persons selling or supplying prescription only medicines to
any person employed or engaged in connection with a scheme for testing the
quality and checking the amount of drugs and appliances supplied under the Health
Insurance (Jersey) Law 1967, or under any subordinate
legislation made under that law.
|
3. All prescription only medicines.
|
3.(1) The
sale or supply shall be subject to the presentation of an order signed by or
on behalf of the person so employed or engaged.
(2) The order shall specify the status of the person signing it,
and the amount of the prescription only medicine required.
|
|
|
(3) The sale or supply shall be only for the purposes of a
scheme to which paragraph 3 of column 1 of this Part of this Schedule refers.
|
4. Certified midwives.
|
4. Prescription only medicines containing any of the following
substances –
Chloral hydrate
Dichloral-phenazone Ergometrine maleate Pentazocine
hydrochloride
Phytomenadrone
Triclofos sodium
|
4. The sale or supply shall be only in the course of the
midwife’s professional practice and, in the case of Ergometrine
maleate, only when contained in a medicinal product that is not for
parenteral administration.
|
5. Persons lawfully conducting retail pharmacy businesses.
|
5. Prescription only medicines (not being for parenteral
administration) that are of any of the following descriptions –
|
5. The sale or supply shall be subject to the presentation of an
order signed by a registered optometrist.
|
|
(a) eye drops, or eye ointments, that are prescription only
medicines by reason only that they contain –
(i) 30.0% Sulphacetamide sodium; or
(ii) 0.5% Chloramphenicol;
|
|
|
|
(b) eye ointments that are prescription only medicines by reason
only that they contain –
(i) 30.0% Sulpha-cetamide sodium; or
(ii) 0.5%Chloramphenicol; or
|
|
(c) medicinal products that are prescription only medicines by
reason only that they contain any of the following substances –
Atropine sulphate
Bethanecol chloride
Carbachol
Cyclopentolate
hydrochloride
Homatropine hydrobromide
Hyoscine hydrobromide
Naphazoline hydrochloride
Naphazoline nitrate
Neostigmine methyl-sulphate
Physostigmine salicylate
Physostigmine sulphate
Pilocarpine hydrochloride
Pilocarpine nitrate
Tropicamide.
|
6. Registered optometrists.
|
6. Prescription only medicines listed in paragraph 5 of column 2
of this Part of this Schedule.
|
6.(1) The sale or supply shall be only in the course of the
optician’s professional practice.
(2) The sale shall be only in an emergency.
|
7.(1) Holders
of product licences.
|
7. Prescription only medicines to which the licence relates.
|
7. The sale or supply shall be only –
|
(2) Holders of manufacturer’s licences.
|
|
(a) to a pharmacist, so as to enable that pharmacist to prepare
an entry relating to the prescription only medicine in question in a tablet
or capsule identifi-cation guide or similar publication; and
|
(b) of no greater quantity than is reasonably necessary for that
purpose.
|
8. Pharmacists selling or supplying to persons to whom cyanide
salts may be sold lawfully under the Poisons
(Jersey) Law 1952.
|
8. Amyl nitrite.
|
8. The sale or supply shall only be so far as is necessary to
enable an antidote to be available to persons at risk of cyanide poisoning.
|
PART 2
(Articles 1(2) and
8(1))
Column 1
|
Column 2
|
Column 3
|
Persons exempted
|
Prescription only medicines to which the
exemption applies
|
Conditions
|
1.(1) The Royal National Lifeboat Institution.
(2) Certificated first aiders of the Institution.
|
1. All prescription only medicines.
|
1. The supply shall be only so far as is necessary for the
treatment of sick or injured persons.
|
2. The owner or the master of a ship that does not carry a
doctor on board as part of the ship’s complement.
|
2. All prescription only medicines.
|
2. The supply shall be only so far as is necessary for the
treatment of persons on the ship.
|
3. The operator or commander of an aircraft.
|
3. Prescription only medicines that –
(a) are not for parenteral administration; and
(b) have been sold or supplied to the operator or commander of
the aircraft in response to an order in writing signed by a doctor.
|
3.(1) The supply shall be only so far as is necessary for the
immediate treatment of sick or injured persons on the aircraft.
(2) The supply shall be in accordance with the written
instructions of a doctor as to the circumstances in which prescription only
medicines of the description in question are to be used on the aircraft.
|
4. Persons authorized by licences granted under Article 4
of the Misuse of Drugs (General Provisions) (Jersey)
Order 1989 to supply a controlled drug.
|
4. Prescription only medicines (being controlled drugs) whose
supply is authorized by the licence.
|
4. The supply shall be subject to the conditions, in the
circumstances and to the extent specified in the licence.
|
5. Persons requiring prescription only medicines to enable them,
in the course of any business carried on by them, to comply with any
requirements under any enactment in respect of the medical treatment of their
employees.
|
5. Prescription only medicines specified in the enactment.
|
5.(1) The supply shall be only to enable the person to comply
with any such requirements.
(2) The supply shall be subject to such conditions and in such
circumstances as may be specified in the enactment.
|
6. Persons operating an occupational health scheme.
|
6. Prescription only medicines sold or supplied to such a person
in response to an order in writing signed by a doctor or a registered nurse.
|
6.(1) The supply shall be only in the course of the scheme.
(2) The person supplying the prescription only medicine shall be
–
(a) a doctor; or
|
(b) a registered nurse acting in accordance with the written
instructions of a doctor as to the circumstances in which prescription only
medicines of the description in question are to be used in the course of the
scheme.
|
PART 3[14]
(Articles 1(2)
and 8(2))
Column 1
|
Column 2
|
Column 3
|
Persons exempted
|
Prescription only medicines to
which the exemption applies
|
Conditions
|
1. Chiropodists, registered
under the Health Care (Registration)
(Jersey) Law 1995, who hold
certificates of competence in the use of analgesics issued by or with the
approval of the Chiropodists Board of the United Kingdom.
|
1. Prescription only medicines
for parenteral administration that contain, as the sole active ingredient,
not more than one of the following substances –
|
1. The administration shall be
only in the course of the chiropodist’s professional practice.
|
|
Bupivacaine hydrochloride
|
|
Bupivacaine hydrochloride with
adrenaline, where the maximum strength of the adrenaline does not exceed 1 mg
in 200 ml of bupivacaine hydrochloride
|
Lignocaine hydrochloride
|
Lignocaine hydrochloride with
adrenaline, where the maximum strength of the adrenaline does not exceed 1 mg
in 200 ml of lignocaine hydrochloride
|
Mepivacaine hydrochloride
|
Prilocaine hydrochloride
|
2. Certified midwives.
|
2. Prescription only medicines
for parenteral administration that contain any of the following substances
(but no other substance specified in column 1 of Part I of the First Schedule
to this Order) –
|
2. The administration shall be
only in the course of the midwife’s professional practice and, in the
case of Lignocaine, Lignocaine hydrochloride and Promazine hydrochloride,
shall be only while attending on a woman in childbirth.
|
|
Ergometrine maleate
|
|
Levallorphan tartrate
|
Lignocaine
|
Lignocaine hydrochloride
|
Naloxone hydrochloride
|
Oxytocins,
|
Natural and Synthetic
|
Pentazocine lactate
|
Pethidine
|
Pethidine hydrochloride
|
Phytomenadione
|
Promazine hydrochloride.
|
3. The owner or the master of a
ship that does not carry a doctor on board as part of the ship’s
complement.
|
3. All prescription only
medicines that are for parenteral administration.
|
3. The administration shall be
only so far as is necessary for the treatment of persons on the ship.
|
4. The operator or commander of
an aircraft.
|
4. Prescription only medicines
for parenteral administration that have been sold or supplied to the operator
or commander of the aircraft in response to an order in writing signed by a
doctor.
|
4.(1) The administration shall
be only so far as is necessary for the immediate treatment of sick or injured
persons on the aircraft.
|
|
|
(2) The administration shall be
in accordance with the written instructions of a doctor as to the
circumstances in which prescription only medicines of the description in question
are to be used on the aircraft.
|
5. Persons operating an
occupational health scheme.
|
5. Prescription only medicines
for parenteral administralion that have been sold or supplied to such a
person in response to an order in writing signed by a doctor or a registered
nurse
|
5.(1) The administration shall
be only in the course of the scheme.
(2) The person administering
the prescription only medicine shall be –
(a) a doctor;
|
|
|
(b) a person acting in
accordance with the directions of a doctor; or
|
(c) a registered nurse acting
in accordance with the written instructions of a doctor as to the
circumstances in which prescription only medicines of the description in
question are to be used in the course of the scheme.
|
6. Persons who hold
certificates of proficiency in ambulance paramedical skills issued by or with
the approval of the Secretary of State of the United Kingdom, or persons who
are state registered paramedics.
|
6. The following prescription
only medicines for parenteral administration –
|
6. The administration shall be
only for the immediate, necessary treatment of sick or injured persons and,
in the case of a prescription only medicine containing Heparin sodium, shall
be only for the purpose of cannula flushing.
|
|
(a) Diazemuls (product licence
number 10183/00001);
|
|
(b) Gelofusine (product licence
number 00183/5025R); and
|
(c) medicines containing the
substances Ergometrine Maleate 500mcg per ml with Oxytocin 5 iu per ml, but
no other active ingredient:
|
(d) prescription only medicines
that contain one or more of the following substances, (but no other active
ingredient)-
|
Adrenaline acid tartrate
|
Benzylpenicillin
|
Frusemide
|
Glucose
|
Heparin sodium
|
Lignocaine hydrochloride
|
Metoclopramide
|
Morphine Sulphate
|
Nalbuphine hydrochloride
|
Naloxone hydrochloride
|
Polygeline
|
Sodium bicarbonate
|
Sodium chloride.
|
Streptokinase
|
SCHEDULE 3
(Articles 9(3)(c) and (4)(a))
SUBSTANCES THAT MUST NOT BE
CONTAINED IN A PRESCRIPTION ONLY MEDICINE EXEMPTED BY ARTICLE 9
Ammonium
Bromide
|
Amylobarbitone
|
Amylobarbitone Sodium
|
Barbitone
|
Barbitone Sodium
|
Butobarbitone
|
Butobarbitone Sodium
|
Calcium Bromide
|
Calcium Bromidolactobionate
|
Cyclobarbitone
|
Cyclobarbitone Calcium
|
Embutramide
|
Fencamfamin Hydrochloride
|
Fluanisone
|
Heptabarbitone
|
Hexobarbitone
|
Hexobarbitone Sodium
|
Hydrobromic Acid
|
Meclofenoxate Hydrochloride
|
Methohexitone Sodium
|
Methylphenobarbitone
|
Pemoline
|
Pentobarbitone
|
Pentobarbitone Sodium
|
Phenobarbitone
|
Phenobarbitone Sodium
|
Phenylmethylbarbituric Acid
|
Piracetam
|
Potassium Bromide
|
Prolintane Hydrochloride
|
Quinalbarbitone
|
Quinalbarbitone Sodium
|
Quinidine
Phenylethylbarbiturate
|
Secbutobarbitone
|
Secbutobarbitone Sodium
|
Sodium Bromide
|
Strychnine Hydrochloride
|
Tacrine Hydrochloride
|
Thiopentone Sodium
|
Note (for information):
|
The restriction in
Article 9(3)(c) is subject to Article 9(4), in respect of
Phenobarbitone and Phenobarbitone Sodium for use in the treatment of
epilepsy.
|
SCHEDULE 4[15]
(Articles 6(2)(ca) and 6A(2))
clinical management plan
1 Information
to be included in clinical management plan
A clinical management plan must include –
(a) the
name of the patient to whom the plan relates;
(b) the illness or
conditions in relation to which the supplementary prescriber may give a
prescription or administer (or direct the administration of) a medicinal
product;
(c) the date on which the
plan is to take effect and the date or dates when it is subject to review by
the doctor or dentist who is a party to the plan;
(d) the class or
description of medicinal product that may be prescribed by a supplementary
prescriber or administered by, or under the direction of, a supplementary
prescriber;
(e) any restrictions or
limitations as to the strength or dose, or period of use, of any medicinal
product which may be prescribed by or administered by, or under the direction
of, the supplementary prescriber;
(f) any relevant
warnings about the known sensitivities of the patient to, or known difficulties
of the patient with, particular medicinal products;
(g) arrangements for the
notification of suspected or known adverse reactions to –
(i) the
medicinal product referred to in paragraph (d), and
(ii) any
other medicinal product taken at the same time or over the same period;
(h) the circumstances in
which the supplementary prescriber should refer to, or seek the advice of, the
doctor or dentist who is a party to the plan.